

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C07D 513/04, A61K 31/519, 31/426, A61P 17/06, 29/00 // (C07D 513/04, 277:00, 239:00)

A1

(11) International Publication Number:

WO 00/09511

(43) International Publication Date:

24 February 2000 (24.02.00)

(21) International Application Number:

PCT/SE99/01333

(22) International Filing Date:

3 August 1999 (03.08.99)

(30) Priority Data:

9802729-5

13 August 1998 (13.08.98) SE

-5 13 August 1996 (13.08.98) 51

- (71) Applicant (for all designated States except MG US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts. WD4 8DH (GB).
- (71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): AUSTIN, Rupert [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). BAXTER, Andrew [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). BONNERT, Roger [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). HUNT, Fraser [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). KINCHIN, Elizabeth [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11

5RH (GB). WILLIS, Paul [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).

- (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).
- (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NOVEL THIAZOLOPYRIMIDINE COMPOUNDS

$$R^{1} \longrightarrow N \longrightarrow N \longrightarrow S-R^{2} \qquad (1)$$

(57) Abstract

The invention provides certain thiazolopyrimidine compounds of general formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
\mathbf{BF}	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
\mathbf{BG}	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
$\mathbf{E}\mathbf{E}$	Estonia	LR	Liberia	SG	Singapore		

20

25

30

NOVEL THIAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

The compound 2,7-diamino-5-methylmercapto-thiazolo[4,5-d]pyrimidine is known from J. Amer. Chem. Soc., 73, 4226 - 4227 (1951).

10 Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1α and 1β (MIP- 1α and MIP- 1β).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug

10

15

20

development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

In accordance with the present invention, there is therefore provided a compound of general formula

$$R^{1}$$
 N
 $S-R^{2}$
 (I)

wherein R¹ represents a hydrogen atom, or a group -NR³R⁴;

 R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl or C_1 - C_8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_6 alkyl and trifluoromethyl groups, or R^3 and R^4 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from

trifluoromethyl groups,

15

20

30

-NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 10 , -NR 8 COR 9 , and C $_1$ -C $_6$ alkyl optionally substituted by one or more substituents independently selected from halogen atoms and -NR 11 R 12 and -OR 7 groups;

X represents a group -OH or -NR ¹³R ¹⁴;

R¹³ and R¹⁴ each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C₁-C₄ alkylphenyl substituent group, or a C₃-C₇ carbocyclic, C₁-C₈ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group, which latter four groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹, morpholinyl, C₁-C₄ alkyl, C₃-C₆ cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -NR⁸COR⁹, -SO₂NR⁵R⁶, NR⁸SO₂R⁹, C₁-C₆ alkyl and

or R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR⁷, -NR⁸COR⁹, and C₁-C₆ alkyl optionally substituted by one or more substituents independently selected from halogen atoms and phenyl, -NR¹¹R¹² and -OR⁷ groups;

 R^2 represents a C_1 - C_6 alkyl or C_2 - C_6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one or more substituents independently selected from halogen atoms and nitro,

C₁-C₆ alkyl, trifluoromethyl, -OR⁷, -C(O)R⁷, -SR¹⁰, -NR¹⁵R¹⁶ and phenyl groups; R⁵ and R⁶ each independently represent a hydrogen atom or a C₁-C₆ alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR¹⁷ and -NR¹⁵R¹⁶, or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 4- to

7-membered saturated heterocyclic ring system optionally comprising a further heteroatom

25

30

selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, $-OR^{17}$, $-COOR^{17}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SONR^{15}R^{16}$, and C_1 - C_6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and $-NR^{15}R^{16}$ and $-OR^{17}$ groups; R^7 and R^9 each independently represent a hydrogen atom or a C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group, each of which may be optionally substituted by one or more (e.g. one, two, three or four) substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine), phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$; and each of R^8 , R^{10} , R^{11} , R^{12} , R^{15} , R^{16} and R^{17} independently represents a hydrogen atom or a C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group; with the proviso that when R^1 and X both represent $-NH_2$, then R^2 does not represent a methyl group;

or a pharmaceutically acceptable salt or solvate thereof.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Where a substituent in an alkenyl group is a phenoxy group, the phenoxy group is not attached to an unsaturated carbon atom. A carbocyclic group is a saturated hydrocarbyl group that may be monocyclic or polycyclic (e.g. bicyclic). Similarly, a saturated heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic).

In formula (I) above, the group R^1 represents a hydrogen atom, or a group $-NR^3R^4$.

Particularly advantageous compounds of formula (I) are those in which R^1 represents a group $-NR^3R^4$.

Preferably, R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or C_1 - C_8 , particularly C_1 - C_6 , alkyl group (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl,

20

25

t-butyl, pentyl, hexyl, heptyl or octyl), which latter two groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl or t-butyl), C_3 - C_6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and trifluoromethyl groups, or R^3 and R^4 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one, two or three substituent groups independently selected from

-NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 10 , -NR 8 COR 9 , and C $_1$ -C $_6$, particularly C $_1$ -C $_4$, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and -NR 11 R 12 and -OR 7 groups.

Particularly advantageous compounds of formula (I) are those in which R^3 and R^4 each independently represent a hydrogen atom, or a C_1 - C_6 alkyl group substituted by a -CONR⁵R⁶ or imidazolyl (e.g. 1*H*-imidazol-4-yl) group.

Preferably, R^2 represents a C_1 - C_6 alkyl or C_2 - C_6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally

substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and nitro, C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), trifluoromethyl, -OR⁷, -C(O)R⁷, -SR¹⁰, -NR¹⁵R¹⁶ and phenyl groups.

5

Particularly advantageous compounds of formula (I) are those in which R^2 represents a C_1 - C_6 alkyl group optionally substituted by a phenyl, halophenyl (e.g. 2,3-difluorophenyl) or -OR⁷ (e.g. phenoxy) group.

10

Preferably, R^5 and R^6 each independently represent a hydrogen atom or a C_1 - C_6 , particularly C_1 - C_4 , alkyl or phenyl group, each of which may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine), phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$, or

15

 R^5 and R^6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms (e.g. one or two oxygen and/or nitrogen atoms), which ring system may be optionally substituted by one, two or three substituent groups independently selected from phenyl, $-OR^{17}$, $-COOR^{17}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SONR^{15}R^{16}$, and C_1-C_6 , particularly C_1-C_4 , alkyl (e.g. methyl, ethyl,

20

propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and $-NR^{15}R^{16}$ and $-OR^{17}$ groups.

25

30

Preferably, R^{13} and R^{14} each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C_1 - C_4 alkylphenyl substituent group, or a C_3 - C_7 carbocyclic, C_1 - C_8 , particularly C_1 - C_6 , alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl or octyl), C_2 - C_6 alkenyl (ethenyl, propenyl, butenyl, pentenyl or hexenyl) or C_2 - C_6 alkynyl (ethynyl, propynyl, butynyl, pentynyl or hexynyl) group, which latter four groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine,

15

20

bromine or iodine) and -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, $-SO_2R^{10}, -SO_2NR^5R^6, -NR^8SO_2R^9, \ morpholinyl, \ C_1-C_4 \ alkyl \ (e.g. \ methyl, \ ethyl, \ alkyl \ (e.g. \ methyl, \ ethyl, \ ethyl,$ propyl, isopropyl, butyl or t-butyl), C₃-C₆ cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and cyano, nitro, -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -NR⁸COR⁹, -SO₂NR⁵R⁶, NR⁸SO₂R⁹, C₁-C₆, particularly C₁-C₄, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and trifluoromethyl groups, or R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one, two or three substituent groups independently selected from -NR⁵R⁶, -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , and C $_1$ -C $_6$, particularly C $_1$ -C $_4$, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and phenyl, -NR¹¹R¹² and -OR⁷ groups;

Particularly advantageous compounds of formula (I) are those in which one of R 13 and R 14 represents a hydrogen atom and the other of R 13 and R 14 represents a C₁-C₆ alkyl group substituted by an -OR 7 group, e.g. -CH(CH₂CH₃)CH₂OH, -C(CH₃)₂CH₂OH or CH(CH₂CH(CH₃)₂)CH₂OH.

Particularly preferred compounds of the invention include:

- (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
- 25 (S)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - 2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 5-[[(3-Phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - (\pm) -2-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
- ³⁰ 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethanol,

- 5-(Pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[[2-(Diethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(3-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[[2-(Acetylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - (\pm) -2-[(2,3-Dihydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[[2-(4-Morpholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(1-Methylethyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - (\pm) -2-[(2-Hydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(2-Hydroxy-2-methylpropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(2-Hydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - (2S,3R)-3-Hydroxy-2-[(7-oxo-5-(pentylthio)-4H-thiazolo[4,5-d]pyrimidin-2-yl]-amino)butanamide,
- N^7 -[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 3-[(2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-1-propanol,
 - N^7 -Cyclohexyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
- (±)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-1,2-propanediol,
 - N^7 -(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 5-(Pentylthio)- N^7 -propylthiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -Cyclopentyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
- N^7 -Cyclopropyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,

- N^7 -(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
- (±)-1-[(2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-2-propanol,
- $(\text{exo})-N^7$ -Bicyclo[2.2.1]hept-2-yl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
- 2-[2-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]ethanol,
- $(\pm)-N^7-(2-\text{Methylbutyl})-5-(\text{pentylthio})$ thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 1-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
 - N^7 -[(2-Aminophenyl)methyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - (E)-2-Amino-5-[(3-phenyl-2-propenyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[3-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[[(4-trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3,5-dibromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-nitrophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-iodophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-A mino-5-[[(4-chloro-2-nitrophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 25 2-Amino-5-[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl]methyl]thio]thiazolo[<math>(4,5-d)pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- ³⁰ 2-Amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,

- 2-Amino-5-[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one, 3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2,2-dimethyl-1-propanol,
- (\pm) - α -[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-
- yl]amino]methyl]benzenemethanol,
 - (R)- β -[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]benzenepropanol,
 - 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethanol,
 - (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-diamondal (2R)-2-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino[4,5-d]pyrimidin-7-y
- 10 methylpentanol,

- $(\pm)-1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,\\$
- $\label{eq:continuous} $$(\pm)-\beta-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol,$
- (±)-3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,2-propanediol,
- 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]propylamino]ethanol,
- (\pm) -1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-pyrrolidinol,
- (\pm) -1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinol,
- 1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-piperidinol,
- 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2,2-dimethyl-1-propanol,
 - (\pm) -2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - (\pm) - α -[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-amino]methyl]benzenemethanol,
 - 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - 6-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-hexanol,

- $\label{lem:conditional} $$4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-amino]cyclohexanol,$
- (R)- β -[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-amino]benzenepropanol,
- (\pm) -2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]-amino] ethanol, \\$
- (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentanol,
 - $\label{lem:continuous} $$(\pm)-1-Amino-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,$
 - $\label{eq:continuous} $$(\pm)-1-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,$
- 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-2-ethyl-1,3-propanediol,
 - (\pm) - β -[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol,
 - (±)-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,2-propanediol,
 - 2-[[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]amino]ethanol,
 - 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- (\pm)- α -[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-3,4-dichlorobenzenepropanol,
 - 1-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
 - 2-[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-
- 30 yl]amino]ethoxy]ethanol,

20

- 5-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
- (2*S*)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-(methylthio)-1-butanol,
- 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]butylamino]ethanol,
 - 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]propylamino]ethanol,
 - 2,2'-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]imino]bisethanol,
 - 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-(2-hydroxyethyl)amino]methyl]phenol,
 - 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-(2-hydroxyethyl)amino]-1-propanol,
- (±)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-pyrrolidinol,
 - (*trans*)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-hydroxy-*L*-proline phenylmethyl ester,
 - (±)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinemethanol,
 - (\pm) -1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinol,
 - (2*S*)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-2-pyrrolidinemethanol,
- 1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-piperidinol,
 - (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - (2*S*)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,

- (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
- 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1, 3-propanediol,
- 5 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
 - $5-[[(2,3-\text{Difluorophenyl})\text{methyl}]\text{thio}]-N^7-(2-\text{fluoroethyl})\text{thiazolo}[4,5-d]$ pyrimidine-2,7-diamine,
 - (1R-trans) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclopentanol,
- (1S-trans) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclopentanol,
 - $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[(phenylmethyl)thio]thiazolo}[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl] amino]-2\hbox{-}methyl-1\hbox{-}propanol,$
- yl]amino]-1-propanol,
 - 2-[[2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - $(\pm)-2-[[2-Amino-5-[[(2,3-difluor ophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-difluor ophenyl]thio]thiazolo[4,5-d]pyrimidin-7-difluor ophenyl]thiazolo[4,5-d]pyrimidin-7-difluor ophenylli ophenylli ophenylli ophenylli ophenyl$
- yl]amino]-1-butanol,
 - (1S,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclohexanol,
 - $\label{eq:continuous} $$(\pm)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,$

WO 00/09511 PCT/SE99/01333

- 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,
- (2*R*)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- 5 (±)-1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,
 - 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1,3-propanediol,
 - 1-[[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-cyclohexanol,

- (2*R*)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-(2-aminoethyl)amino]-1-ethanol,
- 2-[2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]-1-ethanol,
 - (αS) - α -[(1R)-1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]ethyl]-benzenemethanol,
 - 1-[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-piperidinol,
 - $5-[[(2,3-\text{Difluorophenyl})\text{methyl}]\text{thio}]-N^7-\text{ethyl-thiazolo}[4,5-d]$ pyrimidine-2,7-diamine, $5-[[(2,3-\text{Difluorophenyl})\text{methyl}]\text{thio}]-N^7-(2-\text{propenyl})-\text{thiazolo}[4,5-d]$ pyrimidine-2,7-diamine,
 - (1*S*,2*S*)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-phenyl-1,3-propanediol,
 - 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,3-propanediol,
 - 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol,

- (\pm)-5-[[(2,3-Difluorophenyl)methyl]thio]- N^7 -(2-methoxy-1-methylethyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine,
- N^7 -Cyclopropyl-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidine-2,7-diamine,
- 5 (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 4-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - $5-[[(2,3-\text{Difluorophenyl})\text{methyl}]\text{thio}]-N^7-[2-(1H-\text{imidazol-4-yl})\text{ethyl}]-\text{thiazolo}[4,5-(1H-\text{imidazol-4-yl})\text{ethyl}]$
- 10 d]pyrimidine-2,7-diamine,

 - d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1H-indol-3-yl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluor ophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethyl]thio]-2-[(1-naphthalenylmethylmethyl]thio]-2-[(1-naphthalenylmethylme
- 20 d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,2-diphenylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide,
 - 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2-fluoroethyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2-fluoroethyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2-fluoroethyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2-fluoroethyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2-fluoroethyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-[(2-fluoroethyl)amino]th
- 10 d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-(Cyclopropylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - $\label{lem:conditional} $$(\pm)-2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol,$
- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 N-[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-d]pyrimidin-2-yl]-DL-serine, methyl ester,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1H-indol-3-yl)ethyl]amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide,
- 2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one,

- 2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- $2-[[2-[(1,1-\mathrm{Dimethylethyl})\mathrm{amino}]-5-[(\mathrm{phenylmethyl})\mathrm{thio}]\mathrm{thiazolo}[4,5-d]\mathrm{pyrimidin-}7-\mathrm{yl}]\mathrm{amino}]-2-\mathrm{methyl-}1-\mathrm{propanol},$
- 5 N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-DL-alanine, methyl ester,
 - 4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-cyclohexanol,
 - 2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-Methyl-2-[[2-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-L-valine, ethyl ester,
 - (2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- 20 d]pyrimidin-2-yl]amino]-4-methyl-pentanamide,
 - 2-Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[[(4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[(2-Fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-Methyl-2-[[2-[[(3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- 30 d]pyrimidin-7-yl]amino]-1-propanol,

 (αR) - α -[(1S)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,

2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(3,4,5-

trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,

- 5 2-Methyl-2-[[2-[(1*R*-trans)-(2-phenylcyclopropyl)amino]-5-
 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-(1H-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-[(1,1-Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-
- 10 yl]amino]-2-methyl-1-propanol,
 - (±)-2-Methyl-2-[[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - (\pm)-2-Methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[[(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1,3-propanediol,
 - 2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-
- yl]amino]-2-methyl-1-propanol,
 - (2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-3,3-dimethyl-1-butanol,
 - (αS) - α -[(1R)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-

- benzenemethanol,
 - 2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

- (\pm) -2-Methyl-2-[[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[[(4-Methoxyphenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 5 2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - $2-[[2-(1H-\mathrm{Imidazol-4-yl})\mathrm{ethyl}]\mathrm{amino}]-5-[(\mathrm{phenylmethyl})\mathrm{thio}]\mathrm{thiazolo}[4,5-d]\mathrm{pyrimidin-7-yl}]\mathrm{amino}]-2-\mathrm{methyl-1-propanol},$
 - 2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-
- yl]amino]-2-methyl-1-propanol,
 - (2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-butanol,
 - 2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-butanol,
 - (1*S*,2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol,
 - (±)-2-[[2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- 20 d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - $\label{eq:continuous} $$(\pm)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol,$
- 2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide,
 - (\pm)-2-[[2-[[1-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-propanol,
 - (1R,2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl)thiazolo[4,5-dimethyl]amino]-5-[(phenylmethyl]amino]-5-
- 30 d]pyrimidin-2-yl]amino]-cyclohexanol,

- (αS) - α -[(1R)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-
- [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,
- $\label{eq:continuous} (\pm)-2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,$
- 5 (2R)-4-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
 - N-[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester,
 - $(\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-instance of the context of$
- od]pyrimidin-7-yl]amino]-1-butanol,
 - $\label{eq:continuous} $$(\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,$
 - (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-
 - furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
- N-[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester,
 - (\pm)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - $(\pm)-4-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-(phenylmethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-(phenylmethyl)propyl]amino]-5-[(phenylmethyl)propylmethyl]amino]-5-[(phenylmethyl)propylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylmethylpropylm$
- 20 d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
 - (\pm)-4-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
 - 4-[2-[[7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-
 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
- (\pm)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
 - N^7 -Ethyl- N^2 -[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thiothiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 - N^2 -[2-(1*H*-Imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]- N^7 -(3-pyridinylmethyl)-
- thiazolo[4,5-d]pyrimidine-2,7-diamine,

- (\pm)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-butanol,
- (\pm) -2-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-propanol,
- 5 (2*R*)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - $\label{eq:continuous} $$(\pm)-1-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,$
 - 5-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
 - 1-[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,
 - (\pm)-1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinecarboxamide,
- 2-[Ethyl[2-[[2-(1*H*-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol,
 - N^2 -[2-(1*H*-Imidazol-4-yl)ethyl]- N^7 , N^7 -dimethyl-5-[(phenylmethyl)thio]- thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -[2-(Diethylamino)ethyl]- N^7 -ethyl- N^2 -[2-(1*H*-imidazol-4-yl)ethyl]-5-
- 20 [(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^2 -(2-Phenoxyethyl)-5-[(phenylmethyl)thio]- N^7 -(3-pyridinylmethyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^2 -(2-Phenoxyethyl)- N^7 -[1-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidine-2,7-diamine,
- 25 2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - (\pm) -2-[[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - (\pm) -4-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- 30 d[pyrimidin-7-yl]amino]-1-pentanol,

- 1-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,
- 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - (2*R*)-2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - *N*-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester,
 - (2*R*)-2-[[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - N-[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester,
- (±)-2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol,
 - 2-[2-[[7-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxy-1-ethanol,
 - 2-[2-[[7-[(1-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-2-[(phenylmethyl]thiazolo[4,5-d]pyrimidin-2-[(phenylmethyl]thiazolo[4,5-d]pyrimidin-2-[(phenylmethyl]thiazolo[4,5-d]pyrimidin-2-[(phenylmethyl]thiazolo[4,5-d]pyrimidin-2-[(phenylmethyl]
- yl]amino]ethoxy]-1-ethanol,
 - $\label{eq:continuous} $$(\pm)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,$
 - 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- (2R)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - 2-[Cyclohexyl-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol,
 - (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-
- 30 yl]amino]-1-propanol,

- (\pm) -N-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,
- $(\pm)-N-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,$
- N-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,
 - N-[2-[[7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-
 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,
 - N^7 -(2-Methoxyethyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-
- 10 d]pyrimidine-2,7-diamine,
 - N^7 -(2-Ethoxyethyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine,
- (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
 - (\pm) -1-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 2-propanol,
 - (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-butanol,
 - $\label{eq:continuous} $$(\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,$
 - (2R)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- (±)-N,N-Diethyl-1-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinecarboxamide,
 - (2R)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - $(\pm)-2-[[2-[(3-\mathrm{Hydroxypropyl})amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-10-2-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-10-2-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-10-2-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-10-2-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimidin-7-[(phenylmethyl)thiazolo[4,5-d]pyrimid$
- 30 yl]amino]-1-butanol,

 (\pm) -2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,

2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino-acetamide,

4-[1-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-3-azetidinyl]-1-piperazinesulfonamide,

3-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,

2-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-

10 d]pyrimidin-7-yl]amino]-1-propanol,

 (\pm) -2-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,

(2R)-4-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,

2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-7(4H)-one,

 (\pm) -2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-7(4H)-one,

and their pharmaceutically acceptable salts and solvates.

20

According to the invention there is also provided a process for the preparation of a compound of formula (I) which comprises:

(a) when X represents -OH and R¹ is NH₂, heating a compound of general formula

wherein R² is as defined in formula (I); or

(b) when X represents -OH and R¹ is NH₂, reacting a compound of formula

formula

10

15

with a compound of general formula (IV), $R^2 - L^1$, wherein L^1 represents a leaving group such as a halogen atom (e.g. chlorine) and R^2 is as defined in formula (I); or

(c) when X represents -OH or $-NR^{13}R^{14}$ and R^1 is a hydrogen atom, reacting a corresponding compound of formula (I) in which R^1 is NH_2 , with a diazotizing agent; or (d) when X represents -OH and R^1 is a group $-NR^3R^4$, reacting a compound of general

wherein L^2 represents a leaving group such as a halogen atom (e.g. bromine) and R^2 is as defined in formula (I), with a compound of general formula (VI), R^3R^4NH , wherein R^3 and R^4 are as defined in formula (I); or

(e) when X represents -NR¹³R¹⁴ and R¹ represents -NR³R⁴, reacting a compound of general formula

wherein L³ represents a leaving group such as a halogen atom (e.g. chlorine) and R², R³ and R⁴ are as defined in formula (I), with a compound of general formula (VIII), NHR¹³R¹⁴, wherein R¹³ and R¹⁴ are as defined in formula (I); or

(f) when X represents -NR¹³R¹⁴ and R¹ represents -NR³R⁴, reacting a compound of general formula

10

15

20

$$L^{4} \longrightarrow N \longrightarrow N \longrightarrow S^{-R^{2}}(IX)$$

wherein L^4 is a leaving group (e.g. bromine), L^5 is a leaving group (e.g. chlorine) and R^2 is as defined in formula (I), initially with a compound of formula (VI) as defined in (d) above followed by reaction with a compound of formula (VIII) as defined in (e) above;

and optionally after (a), (b), (c), (d), (e) or (f) forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).

Process (a) is conveniently carried out in the presence of a solvent or solvent mixture such as dimethylformamide/water at a temperature in the range from e.g. 50 to 150°C.

Process (b) is conveniently carried out in an organic solvent such as tetrahydrofuran or dimethyl sulphoxide/dimethylformamide mixture, optionally in the presence of a base such as potassium *tert*-butoxide or diisopropylamide.

Process (c) is conveniently carried out in an organic solvent such as tetrahydrofuran. Examples of suitable diazotizing agents to use include *tert*-butyl nitrite.

Process (d) is conveniently carried out in an organic solvent such as tetrahydrofuran, e.g. at a temperature of 50°C for 5 hours.

Process (e) is conveniently carried out in an organic solvent such as tetrahydrofuran with heating for a period in the range from 1 day to 3 weeks.

Process (f) is conveniently carried out in an organic solvent such as tetrahydrofuran or N-methylpyrrolidine at a temperature between 0° and 130°C, with a reaction time of 1 hour to 3 weeks.

20

25

Compounds of formula (II) may be readily prepared by reacting a compound of general formula

$$H_2N$$
 S
 R^2
 (X)

wherein R² is as defined above, with potassium thiocyanate and bromine in dimethylformamide/pyridine.

Compounds of formula (X) are suitably prepared by reacting a compound of formula

with a compound of formula (IV) as defined above.

Compounds of formula (V) may be prepared by reacting a compound of formula (I) in which R^1 is NH_2 , with a diazotizing agent and a halogenating agent. The reaction is conveniently carried out in an organic solvent such as acetonitrile in the presence of a diazotizing agent such as *tert*-butyl nitrite and a halogenating agent such as a trimethylsilyl halide.

Compounds of formula (VII) in which L^3 is a chlorine atom may be prepared by reacting a compound of formula (I) in which X is -OH with phosphorus oxychloride in dimethylaniline under reflux conditions.

Compounds of formula (IX) in which L^4 represents a bromine atom and L^5 represents a chlorine atom may be prepared by reacting a compound of formula (I) in which X is -OH and R^1 is NH_2 with phosphorus oxychloride in dimethylaniline under reflux conditions, followed by reaction with *tert*-butyl nitrite and bromoform.

20

25

30

Compounds of formulae (III), (IV), (VI), (VIII) and (XI) are either commercially available, are well known in the literature or may be prepared easily using known techniques.

- The compounds of formulae (V), (VII) and (IX) are novel intermediates and therefore form a further aspect of the present invention. In formula (V), L² is preferably a bromine atom. In formula (VII), R³ and R⁴ preferably both represent a hydrogen atom. In formula (IX), L³ is preferably a bromine atom and L⁴ is preferably a chlorine atom.
- It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.

The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention, for example tautomers of general formula

wherein R^1 and R^2 are as defined in formula (I), or of general formula

$$R^{1}$$
 N
 N
 N
 $S-R^{2}$
 (I^{n})

wherein R¹ and R² are as defined in formula (I).

Similarly, it will be understood that in the above processes tautomeric forms of the compounds of formulae (II), (III), (IX) and (X) may also be used, for example,

$$H_2N$$
 N
 $S-R^2$

and

10

15

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:

- (1) (the respiratory tract) obstructive airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) (skin) psoriasis, atopical dermatitis, contact dermatitis and other eczmatous
 dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus,
 Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous
 eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;

10

15

- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- (5) (other tissues and systemic disease) multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura;
- (6) (allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- (7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma;
- (8) diseases in which angiogenesis is associated with raised CXCR2 chemokine levels (e.g. NSCLC); and
- (9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis.
- Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
 - In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

25

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

- The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
- The invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
- For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w,

10

15

20

25

30

still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.

The invention will now be further illustrated by reference to the following examples. In the examples the Nuclear Magnetic Resonance (NMR) spectra were measured on a Varian Unity Inova 300 or 400 MHz spectrometer and the Mass Spectrometry (MS) spectra measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer. Where necessary, the reactions were performed under an inert atmosphere of either nitrogen or argon. Chromatography was generally performed using Matrex Silica $60^{\text{(8)}}$ (35-70 micron) or Prolabo Silica gel $60^{\text{(35-70 micron)}}$ suitable for flash silica gel chromatography. High pressure liquid chromatography purification was performed using either a Waters Micromass LCZ with a Waters 600 pump controller, Waters 2487 detector and Gilson FC024 fraction collector or a Waters Delta Prep 4000. The abbreviations m.p. and DMSO used in the examples stand for melting point and dimethyl sulphoxide respectively.

Example 1

5

10

15

20

25

$(2R) \hbox{-} 2 \hbox{-} [[2-Amino-5-[(phenylmethyl)thio]thiazolo} [4,5-d] pyrimidin-7-yl] amino] \hbox{-} 1-but anol$

(a) 7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-amine

2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one (0.89g) (prepared as described in Example 9), phosphorus oxychloride (12mL) and N,N-dimethylaniline (1.2mL) were heated at reflux for 2 hours. The cooled reaction mixture was poured onto ice and water and stirred for 2 hours. Chromatography on silica eluting with methanol/dichloromethane mixtures gave the sub-title chloride.

m.p. 217-218.5°C

MS: APCI(+ve) 309/11 (M+1)

 ^{1}H NMR: δ (DMSO) 4.38 (s,2H), 7.20-7.48 (m,5H) and 8.95 (br s,2H).

$(b) \ \ (2R) - 2 - [[2 - Amino - 5 - [(phenylmethyl)thio]thiazolo[4, 5 - d]pyrimidin - 7 - yl] amino] - 1 - butanol \\$

The chloro compound from step (a) (0.12g) in tetrahydrofuran (3 mL) was treated with (R)-2-amino-1-butanol (0.56g) and the reaction mixture was heated at reflux for 5 days. Dichloromethane and dilute hydrochloric acid were added. The resulting solid was filtered off, washed with water and ether to give the title compound which was obtained containing 0.23 moles of hydrogen chloride and 0.93 moles of water. Yield 0.045g.

m.p. 118-121°C

MS: APCI(+ve) 362 (M+1)

¹H NMR: δ (DMSO) 0.83 (t,3H), 1.45 (m,2H), 1.65 (m,2H), 3.39 (m,2H), 4.31 (q,2H), 4.65 (t,1H), 6.91 (d,1H), 7.17-7.44 (m,5H) and 8.00 (s,2H).

5 Example 2

(S) - 2 - [[2-Amino-5 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino] - 1-butanol

Prepared by the method of Example 1(b) from the chloro compound of Example 1(a) and (S)-2-amino-1-butanol. Obtained as a solid containing 0.7 moles of hydrogen chloride.

mp 204-208°C

10

15

MS: APCI(+ve) 362 (M+1)

¹H NMR: δ (DMSO) 0.82 (t,3H), 1.37-1.74 (m,2H), 3.36-3.52 (m,2H), 4.10 (br s,1H),

4.41 (q,2H), 7.20-7.46 (m,5H), 7.63 (br s,1H) and 8.42 (s,2H).

Example 3

2-Amino-5-[[(2,3-difluor ophenyl)methyl] thio] thiazolo[4,5-d] pyrimidin-7(4H)-one

a) 2-Amino-5-mercapto-thiazolo[4,5-d]pyrimidin-7(4H)-one

Aluminium tribromide (1M in CH_2Br_2 , 15.2ml) was added to a solution of the product of Example 9 (2.0g) in toluene (25ml) and the reaction mixture heated at 60°C for 6 hours.

5

10

15

20

On cooling to room temperature, water (40ml) was added and the resulting solid isolated by filtration then triturated with hot ethanol to afford the sub-title compound (0.8g).

MS: (APCI) 201 (M+H⁺, 100%)

b) 2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one Potassium t-butoxide solution (0.45mL of 1M in tetrahydrofuran) was added to a stirred solution of the product of step a) (0.09g) and 2,3-difluorobenzyl bromide in dimethyl sulphoxide (2mL). After stirring for 3 days, the reaction mixture was poured onto water. The title compound was obtained. Yield 0.065g.

m.p. 310-313°C

MS: APCI(+ve) 327 (M+1)

¹H NMR: δ (DMSO) 4.48 (s,2H), 7.18-7.45 (m,3H), 8.20 (s,2H) and 12.62 (s,1H).

Example 4

 $5\hbox{-}[[(3\hbox{-}Phenoxyphenyl)methyl]thio]thiazolo[4,5\hbox{-}d]pyrimidin-7(4H)\hbox{-}one$

2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one (0.3g) (product of Example 5) was added over 90 minutes to a solution of t-butyl nitrite (0.17mL) in tetrahydrofuran (3mL) at 65°C. After a further 3.5 hours at 65°C, the solvent was evaporated and the residue chromatographed on silica eluting with methanol/dichloromethane mixtures to give the title compound. Yield 0.071g.

25 m.p. 197-198°C

MS: APCI(+ve) 368 (M+1)

¹H NMR: δ (DMSO) 4.49 (s,2H), 6.86-7.38 (m,9H), 9.58 (s,1H) and 13.11 (s,1H).

2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

Prepared by the method of Example 3 using 3-phenoxybenzyl chloride.

m.p. 266-269°C

MS: APCI(+ve) 383 (M+1)

¹H NMR: δ (DMSO) 4.40 (s,2H), 6.81-7.41 (m,9H), 8.15 (s,2H) and 12.55 (s,1H).

Example 6

10

$(\pm)\textbf{-2-}[[2\textbf{-}Amino\textbf{-5-}(pentylthio)thiazolo} [\textbf{4,5-}d] pyrimidin\textbf{-7-}yl] amino]\textbf{-1-}but anol$

$(a) \ \ 7-Chloro-5-(pentylthio) thiazolo [4,5-d] pyrimidin-2-amine$

Prepared by the method of Example 1(a) from 2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one (product of Example 10).

m.p. 176.5-177.5°C

MS: APCI(+ve) 289 (M+1)

¹H NMR: δ (DMSO) 0.88 (t,3H), 1.22-1.42 (m,4H), 1.60-1.74 (m,2H), 3.08 (t,2H) and 8.90 (s,2H).

$\textbf{(b)} \ \ (\pm)\textbf{-2-}[[2\textbf{-}Amino\textbf{-5-}(pentylthio)thiazolo} \\ \textbf{[4,5-d]}pyrimidin\textbf{-7-yl}] \\ \textbf{amino}]\textbf{-1-butanol}$

Prepared by the method of Example 1(b) from the chloro compound of Example 6(a) and the appropriate amine.

m.p. 151-154°C

5 MS: APCI(+ve) 342 (M+1)

¹H NMR: δ (DMSO) 0.82-0.95 (m,6H), 1.22-1.72 (m,8H), 3.04 (m,2H), 3.39-3.56 (m,2H), 4.07 (m,1H), 4.64 (t,1H), 6 88 (d,1H), 7.44 (br s,1H) and 7.96 (s,2H).

Example 7

2-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethanol

Prepared by the method of Example 6(b).

m.p. 192-195°C

MS: APCI(+ve) 314 (M+1)

¹H NMR: δ (DMSO) 0.87 (t,3H), 1.21-1.42 (m,4H), 1.57-1.70 (m,2H), 2.99 (t,2H), 3.37-3.46 (m,2H), 3.46-3.58 (m,2H), 4.71 (t,1H), 7.22 (t,1H) and 7.97 (s,2H).

Example 8

5-(Pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one

Prepared by the method of Example 4.

m.p. 208-209°C

25 MS: APCI(+ve) 256 (M+1)

¹H NMR: δ (DMSO) 0.88 (t,3H), 1.22-1.44 (m,4H), 1.63-1.75 (m,2H), 3.20 (t,2H), 9.57 (s,1H) and 13.06 (s,1H).

Example 9

2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

(a) 6-Amino-2-[(phenylmethyl)thio]-5-thiocyanato-4(1H)-pyrimidinone

6-Amino-2-[(phenylmethyl)thio]-4(1*H*)-pyrimidinone (10.5g) (prepared as described in WO 96/35678) and potassium thiocyanate (25g) in dimethylformamide (200mL) were heated together at 65°C. Pyridine (6.3mL) was added and the solution cooled to 5°C. Bromine (2.2mL) was added slowly and the reaction mixture stirred for 2 hours at 5-10°C. The reaction mixture was poured onto ice and water, stirred for 1 hour and the solid was filtered off. After washing with water and ether a pure sample was obtained after tituration with hot methanol.

15

20

10

m.p. 260-262°C

MS: APCI(+ve) 291 (M+1)

¹H NMR: δ (DMSO) 4.38 (s,2H), 7.21-7.51 (m,5H), 7.70 (br s,2H) and 12.35 (s,1H).

(b) 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

The product of step (a) (7.35g) was heated at 120°C in dimethylformamide (40mL) and water (10mL) for 10 hours. After cooling, the resulting solid was filtered off, washed with water, ether and ethyl acetate to give the title compound containing 0.4 moles of dimethylformamide.

25

m.p. ~325°

MS: APCI(+ve) 291 (M+1)

¹H NMR: δ (DMSO) 4.41 (s,2H), 7.21-7.50 (m,5H), 8.17 (s,2H) and 12.53 (br s,1H).

Example 10

5

2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one

(a) 6-Amino-2-(pentylthio)-5-thiocyanato-4(1H)-pyrimidinone

Prepared by the method of Example 9(a).

m.p. 260-262°C

MS: APCI(+ve) 214 (M+1)

¹H NMR: δ (DMSO) 0.86 (t,3H), 1.22-1.40 (m,4H), 1.56-1.68 (m,2H), 3.10 (t,2H), 7.58 (br s,2H) and 12.30 (s,1H).

(b) 2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one

15 Prepared by the method of Example 9(b).

MS: APCI(+ve) 271 (M+1)


 1H NMR: δ (DMSO) 0.86 (t,3H), 1.24-1.40 (m,4H), 1.58-1.70 (m,2H), 3.12 (t,2H), 8.12 (br s,2H) and 12.49 (s,1H).

Example 11

20

25

${\bf 2\text{-}Bromo\text{-}5\text{-}(pentylthio)thiazolo[4,5\text{-}d]pyrimidin\text{-}7(4H)\text{-}one}$



Trimethylsilyl bromide (0.44mL) was added slowly to a solution at 0°C under nitrogen of t-butyl nitrite (0.42mL) in acetonitrile (2mL). After 30 minute at 0°C, 2-amino-5- (pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one (0.5g) (product of Example 10) was added.

The reaction mixture was stirred at room temperature for 16 hours and the solvent was evaporated. Chromatography on silica eluting with dichloromethane/methanol mixtures gave the title bromide.

5 m.p. 189-191°C

MS: APCI(+ve) 336/7 (M+1)

¹H NMR: δ (DMSO) 0.88 (t,3H), 1.26-1.41 (m,4H), 1.64-1.75 (m,2H), 3.18 (t,2H) and 13.22 (s,1H).

10 **Examples 12-26**

The compounds of Examples 12 to 26 were prepared by heating 2-bromo-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one (product of Example 11) with 5 equivalents of the appropriate amine in tetrahydrofuran at 45°C for 5 hours.

15 Example 12

 $2\hbox{-}[[3\hbox{-}(Dimethylamino)propyl]amino}]\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 356 (M+1)

Example 13

 $2\hbox{-}[[2\hbox{-}(Diethylamino)\hbox{ethyl}] a mino]\hbox{-}5\hbox{-}(pentylthio)\hbox{thiazolo}[4,5\hbox{-}d] pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 370 (M+1)

20

 $2\hbox{-}[[2\hbox{-}(Dimethylamino)\hbox{ethyl}] a mino]\hbox{-}5\hbox{-}(pentylthio)\hbox{thiazolo}[4,5\hbox{-}d] pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 342 (M+1)

Example 15

 $2\hbox{-}[(3\hbox{-}Hydroxypropyl)amino]\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 329 (M+1)

10

5

Example 16

 $2\hbox{-}[[2\hbox{-}(Acetylamino)ethyl] a mino]-5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d] pyrimidin-7(4H)-one$

MS: APCI (+ve) 356 (M+1)

15


Example 17

 $(\pm) - 2 - [(2, 3 - Dihydoxypropyl) amino] - 5 - (pentylthio) thiazolo [4, 5 - d] pyrimidin - 7 (4H) - one$

MS: APCI (+ve) 345 (M+1)

20

 $2\hbox{-}[[2\hbox{-}(4\hbox{-}Morpholinyl)ethyl]amino}]\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$



MS: APCI (+ve) 384 (M+1)

5

Example 19

 $2\hbox{-}[(2\hbox{-}Methoxyethyl)amino}]\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 329 (M+1)

10

Example 20

 $2\hbox{-}[(1\hbox{-}Methylethyl)amino]\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 313 (M+1)

15

Example 21

 $2\hbox{-}(Cyclopropylamino)\hbox{-}5\hbox{-}(pentylthio) thiazolo \hbox{$[4,5$-$d]} pyrimidin\hbox{-}7\hbox{$(4H)$-one}$

MS: APCI (+ve) 311 (M+1)

20

 (\pm) -2-[(2-Hydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 329 (M+1)

5

Example 23

 $2\hbox{-}[[2\hbox{-}(2\hbox{-}Hydroxyethoxy)ethyl]amino}]\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 359 (M+1)

Example 24

 $2\hbox{-}[(2\hbox{-}Hydroxy\hbox{-}2\hbox{-}methylpropyl)amino}]\hbox{-}5\hbox{-}(pentylthio)thiazolo [4,5\hbox{-}d] pyrimidin\hbox{-}7(4H)\hbox{-}one$

15

10

MS: APCI (+ve) 343 (M+1)

Example 25

2-[(2-Hydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one

20

MS: APCI (+ve) 315 (M+1)

(2S,3R)-3-Hydroxy-2-[(7-oxo-5-(pentylthio)-4H-thiazolo[4,5-d]pyrimidin-2-yl]-amino)butanamide

MS: APCI (+ve) 372 (M+1)

Examples 27-43

The compounds of Examples 27 to 43 were prepared by heating 7-chloro-5-(pentylthio)thiazolo[4,5-d]pyrimidin-2-amine (product of Example 6, step a) with 5 equivalents of the appropriate amine in tetrahydrofuran at 45°C for 5 hours.

Example 27

10

15

 N^7 -[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine

MS: APCI (+ve) 355 (M+1)

Example 28

 N^7 -[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine

20 MS: APCI (+ve) 369 (M+1)

N^7 -[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine

MS: APCI (+ve) 341 (M+1)

5

Example 30

3-[(2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-1-propanol

MS: APCI (+ve) 328 (M+1)

10

Example 31

N⁷-Cyclohexyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine

MS: APCI (+ve) 352 (M+1)

15

Example 32

$\label{eq:continuous} (\pm) - 3 - [(2-Amino-5 - ((phenylmethyl)thio)thiazolo[4,5-d]pyrimidin-7 - yl)amino] - 1,2-propanediol$

20 MS: APCI (+ve) 344 (M+1)

 N^7 -(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine

5 MS: APCI (+ve) 328 (M+1)

Example 34

 $5\hbox{-}(Pentylthio)\hbox{-}N^7\hbox{-}propylthiazolo [4,5\hbox{-}d] pyrimidine-2,7\hbox{-}diamine \\$

10 MS: APCI (+ve) 312 (M+1)

Example 35

 $N^7\hbox{-} Cyclopentyl-5\hbox{-}(pentylthio) thiazolo [4,5\hbox{-}d] pyrimidine-2,7\hbox{-}diamine$

15 MS: APCI (+ve) 338 (M+1)

Example 36

 $N^7\text{-}\mathbf{Cyclopropyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine}$

20 MS: APCI (+ve) 310 (M+1)

 N^7 -(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine

5 MS: APCI (+ve) 326 (M+1)

Example 38

 $(\pm) - 1 - [(2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino] - 2-propanol$

10 MS: APCI (+ve) 328 (M+1)

Example 39

 $(\textbf{exo}) - N^7 - \textbf{Bicyclo} \textbf{[2.2.1]} \textbf{hept-2-yl-5-(pentylthio)} \textbf{thiazolo} \textbf{[4,5-d]} \textbf{pyrimidine-2,7-diamine}$

15 MS: APCI (+ve) 364 (M+1)

Example 40

 $2\hbox{-}[2\hbox{-}[2\hbox{-}Amino-5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino] ethoxy] ethanol$

20 MS: APCI (+ve) 358 (M+1)

$(\pm)\text{-}N^7\text{-}(2\text{-}Methylbutyl)\text{-}5\text{-}(pentylthio)thiazolo[4,5\text{-}d]pyrimidine\text{-}2,7\text{-}diamine}$

MS: APCI (+ve) 340 (M+1)

5

Example 42

$1\hbox{-}[[2\hbox{-}Amino\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino]-2\hbox{-}methyl-2\hbox{-}propanol}$

MS: APCI (+ve) 342 (M+1)

10

Example 43

$N^7\hbox{-}[(2\hbox{-}Amin ophenyl)methyl]\hbox{-}5\hbox{-}(pentyl thio) thiazolo [4,5\hbox{-}d] pyrimidine-2,7\hbox{-}diamine$

MS: APCI (+ve) 375 (M+1)

15

20

Examples 44-47

The compounds of Examples 44 to 47 were prepared from 2-amino-5,6-dihydro-5-thioxothiazolo[4,5-d]pyrimidin-7(4H)-one, diisopropylethylamine and the appropriate alkyl halide in dimethyl sulphoxide/dimethylformamide at 60°C. A total of 5 equivalents of base and alkyl halide were added over 3 days.

${\it 2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]} pyrimidin-7 (4H)-one$

MS: APCI (+ve) 321 (M+1)

Example 45

$(E)\hbox{-}2\hbox{-}Amino\hbox{-}5\hbox{-}[(3\hbox{-}phenyl\hbox{-}2\hbox{-}propenyl)\hbox{thio}] thiazolo[4,5\hbox{-}d] pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS: APCI (+ve) 317 (M+1)

10

5

Example 46

2-Amino-5- [[3-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-d]-pyrimidin-7(4H)-one

15 MS: APCI (+ve) 447 (M+1)

2-Amino-5-[[[(4-trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 359 (M+1)

Examples 48-65

The compounds of Examples 48 to 65 were prepared from 2-amino-5,6-dihydro-5-thioxothiazolo[4,5-d]pyrimidin-7(4H)-one (product of Example 3, step a), potassium t-butoxide and the appropriate benzyl halide in dimethyl sulphoxide at room temperature. A total of 1.2 equivalents of base and alkyl halide were used and a reaction time of 24 hours.

Example 48

2-Amino-5-[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 359 (M+1)

Example 49

2-Amino-5-[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 359 (M+1)

Example 50

2-Amino-5-[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 359 (M+1)

Example 51

2-Amino-5- [[(3,5-dibromophenyl)methyl]thio]thiazolo [4,5-d]pyrimidin-7 (4H)-one

10

5

MS: APCI (+ve) 449 (M+1)

Example 52

2-Amino-5- [[(2-ritrophenyl)methyl] thio] thiazolo [4,5-d] pyrimidin-7 (4H) -one

15

MS: APCI (+ve) 336 (M+1)

 $\textbf{2-Amino-5-} \hbox{\tt [[(2-fluorophenyl)methyl]thio]} \hbox{\tt thiazolo[4,5-$d]} pyrimidin-7 \hbox{\tt (4$H)-one}$

MS: APCI (+ve) 309 (M+1)

5

Example 54

2-Amino-5-[[(2-iodophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 417 (M+1)

10

Example 55

2-Amino-5- [[(3-chlorophenyl)methyl]thio]thiazolo [4,5-d]pyrimidin-7 (4H)-one

MS: APCI (+ve) 325 (M+1)

15

Example 56

2-Amino-5-[[(2-chlorophenyl)methyl] thio] thiazolo[4,5-d] pyrimidin-7(4H)-one

MS: APCI (+ve) 325 (M+1)

2-Amino-5-[[(4-chloro-2-nitrophenyl)methyl] thio] thiazolo[4,5-d] pyrimidin-7(4H)-one and the contraction of the contraction

MS: APCI (+ve) 370 (M+1)

Example 58

5

2-Amino-5-[[(3-chloro-4-methoxyphenyl)methyl] thio] thiazolo[4,5-d] pyrimidin-7(4H)-one

10 MS: APCI (+ve) 355 (M+1)

Example 59

2-Amino-5- [[(2,3-dichlorophenyl)methyl] thio] thiazolo[4,5-d] pyrimidin-7(4H)-one

15 MS: APCI (+ve) 359 (M+1)

Example 60

2-Amino-5- [[(3,5-difluor ophenyl) methyl] thio] thiazolo [4,5-d] pyrimidin-7(4H) - one

MS: APCI (+ve) 327 (M+1)

Example 61

2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-defined by the context of t

5 7(4H)-one

MS: APCI (+ve) 427 (M+1)

Example 62

2-Amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 371 (M+1)

Example 63

2-Amino-5-[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

MS: APCI (+ve) 345 (M+1)

2-Amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5-d] pyrimidin-7(4H)-one

MS: APCI (+ve) 369 (M+1)

Example 65

5

15

2-Amino-5-[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-d] pyrimidin-7(4H)-one

10 MS: APCI (+ve) 323 (M+1)

Examples 66-77

The compounds of Examples 66 to 77 were prepared from 7-chloro-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-amine and the appropriate hydroxyamine in dimethyl sulphoxide at 45°C. A total of 6 equivalents of amine were added and the reaction time was 2 days.

Example 66

 $3\hbox{-}[[2\hbox{-}Amino\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7\hbox{-}yl]amino]-2,2\hbox{-}4$

20 dimethyl-1-propanol

MS: APCI (+ve) 376 (M+1)

 $(\pm)-\alpha-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]benzenemethanol$

MS: APCI (+ve) 410 (M+1)

Example 68

5

 $(\textit{R}) - \beta - [[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-$

10 yl]amino]benzenepropanol

MS: APCI (+ve) 424 (M+1)

Example 69

15

2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethanol

MS: APCI (+ve) 334 (M+1)

 $(2R) \hbox{-} 2 \hbox{-} [[2\hbox{-}Amino-5\hbox{-} [(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino] 4-methylpentanol$

MS: APCI (+ve) 390 (M+1)

Example 71

 $(\pm) - 1 - [[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino] - 2 - [(absolution - 1) - (absolution - 1) - ($

10 propanol

5

MS: APCI (+ve) 348 (M+1)

Example 72

15

 (\pm) - β -[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol

MS: APCI (+ve) 458 (M+1)

Example 73

5 propanediol

MS: APCI (+ve) 364 (M+1)

Example 74

2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-

propylamino]ethanol

MS: APCI (+ve) 376 (M+1)

15 **Example 75**

 $(\pm)\textbf{-}1\textbf{-}[2\textbf{-}Amino\textbf{-}5\textbf{-}[(phenylmethyl)thio]thiazolo} \\ [4,5\textbf{-}d] pyrimidin\textbf{-}7\textbf{-}yl]\textbf{-}3\textbf{-}pyrrolidinol$

MS: APCI (+ve) 360 (M+1)

$(\pm)\textbf{-1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinol}$

MS: APCI (+ve) 374 (M+1)

Example 77

5

10

15

$1\hbox{-}[2\hbox{-}Amino\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo} \hbox{$[4,5$-}d] pyrimidin\hbox{-}7-yl]\hbox{-}4-piperidinol$

MS: APCI (+ve) 374 (M+1)

Examples 78-110

The compounds of Examples 78 to 110 were prepared from 7-chloro-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2-amine (prepared by the method of Example 1, step a) using the product of Example 5) and the appropriate hydroxyamine in tetrahydrofuran at 45°C. A total of 6 equivalents of amine were added and the reaction time was 2 days.

3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl]amino-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl]amino-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl]amino-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl]amino-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl]amino-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl]amino-10-[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[-2-Amino-5-[(3-phenoxyphenyl)methyl]

2,2-dimethyl-1-propanol

MS: APCI (+ve) 468 (M+1)

Example 79

 $(\pm) - 2 - [[2-Amino-5 - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - amino] - 1 - butanol$

MS: APCI (+ve) 454 (M+1)

Example 80

10

15

 $(\pm) - \alpha - [[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - \alpha - [[[2-Amino-5-[((3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - \alpha - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - \alpha - [[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl] - \alpha - [[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-yl] - ((3-phenoxyphenyl)methyl] - ((3-phenoxyphenyl)methyll - ((3-phenoxyphenyl)methyll - ((3-phenoxyphenyl)methyll - ((3-phenoxyphenyl)methyll - ((3-phenoxyphenyl)methyll - ((3-phenoxyphenyl)methyll - ((3-phenoxyphenyl)$

amino]methyl]benzenemethanol

MS: APCI (+ve) 502 (M+1)

4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-

1-butanol

5 MS: APCI (+ve) 454 (M+1)

Example 82

 $6\hbox{-}[[2\hbox{-}Amino\hbox{-}5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin\hbox{-}7\hbox{-}yl] amino]-$

1-hexanol

MS: APCI (+ve) 482 (M+1)

Example 83

10

 $4\hbox{-}[[2\hbox{-}Amino\hbox{-}5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin\hbox{-}7\hbox{-}yl] -$

15 amino]cyclohexanol

MS: APCI (+ve) 480 (M+1)

(R)- β -[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-amino]benzenepropanol

MS: APCI (+ve) 516 (M+1)

Example 85

 $(\pm) - 2 - [[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - amino] - 1 - propanol$

MS: APCI (+ve) 440 (M+1)

Example 86

10

 $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]-4,$

15 amino]ethanol

MS: APCI (+ve) 426 (M+1)

(2R) - 2 - [[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - amino] - 4-methylpentanol

MS: APCI (+ve) 482 (M+1)

Example 88

5

10

 $(\pm) -1 - Amino -3 - [[2 - Amino -5 - [[(3 - phenoxyphenyl)methyl]thio]thiazolo [4,5 - d]pyrimidin -7 - yl]amino] -2 - propanol$

MS: APCI (+ve) 455 (M+1)

Example 89

 $(\pm)\textbf{-1-}[[2\textbf{-}Amino\textbf{-}5\textbf{-}[[(3\textbf{-}phenoxyphenyl)methyl]thio}] thiazolo[\textbf{4,5-}d] pyrimidin\textbf{-}7\textbf{-}[(3\textbf{-}phenoxyphenyl)methyl]thio]}$

15 yl]amino]-2-propanol

MS: APCI (+ve) 440 (M+1)

 $2\hbox{-}[[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio]thiazolo[4,5\hbox{-}d]pyrimidin-7-yl]amino]methyl]-2\hbox{-}ethyl-1,3\hbox{-}propanediol}$

5 MS: APCI (+ve) 498 (M+1)

Example 91

 (\pm) - β -[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol

10

15

MS: APCI (+ve) 550 (M+1)

Example 92

 $(\pm) - 3 - [[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-line (\pm) - 3 - [[2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-line (\pm) - [2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-line (\pm) - [2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-line (\pm) - [2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-line (\pm) - [2-Amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-line (\pm) - [2-Amino-5-[(3-phenoxyphenyl)methyl]thiazolo[4,5-d]pyrimidin-7-line (\pm) - [2-Amino-5-[(3-phenoxyphenyl)methylline (\pm) - [2-Am$

yl]amino]-1,2-propanediol

MS: APCI (+ve) 456 (M+1)

 $2 \hbox{-} [[2 \hbox{-} [2 \hbox{-} Amino-5 \hbox{-} [[(3 \hbox{-} phenoxyphenyl)methyl]thio}] thiazolo[4,5 \hbox{-} d] pyrimidin-7-yl] amino] ethyl] ethyl] ethyl[ethyl] ethyl[ethyl] ethyl[ethyl] ethyl[ethyl] ethyl] ethyl[ethyl[ethyl] ethyl[ethyl] ethyl[ethyl[ethyl[ethyl] ethyl[ethyl[$

5 MS: APCI (+ve) 469 (M+1)

Example 94

 $3\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl] amino]-1\hbox{-}propanol$

10

15

MS: APCI (+ve) 440 (M+1)

Example 95

 $(\pm) - \alpha - [[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-left and the second of the seco$

yl]amino]methyl]-3,4-dichlorobenzenepropanol

MS: APCI (+ve) 598 (M+1)

1-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-2-propanol

MS: APCI (+ve) 454 (M+1)

Example 97

 $2\hbox{-}[2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7-yl] amino] ethoxy] ethanol \\$

10

MS: APCI (+ve) 470 (M+1)

Example 98

 $5\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}a]pyrimidin-7\hbox{-}yl]amino]-100$

15 1-pentanol

MS: APCI (+ve) 468 (M+1)

(2S) - 2 - [[2-Amino-5 - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino] - 4 - (methylthio) - 1 - butanol

MS: APCI (+ve) 500 (M+1)

Example 100

 $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7-yl] butylamino] ethanol \\$

MS: APCI (+ve) 482 (M+1)

Example 101

10

 $\hbox{$2$-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]$ thiazolo[4,5-d] pyrimidin-7-lemma and the properties of the propert$

15 yl]propylamino]ethanol

MS: APCI (+ve) 468 (M+1)

2,2'-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-left and the statement of the s

yl]imino]bisethanol

MS: APCI (+ve) 470 (M+1)

Example 103

5

10

15

 $2\hbox{-}[[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]\hbox{-}(2\hbox{-}hydroxyethyl) amino] methyl] phenol$

MS: APCI (+ve) 532 (M+1)

Example 104

 $3\hbox{-}[[2\hbox{-}Amino\hbox{-}5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin\hbox{-}7\hbox{-}yl]\hbox{-}(2\hbox{-}phenoxyphenyl)methyl] thiazolo[4,5\hbox{-}d] pyrimidin\hbox{-}7\hbox{-}yl] thiazolo[4,5\hbox{-}d] pyrimidin\hbox{-}7\hbox{-}yl] thiazolo[4,5\hbox{-}d] pyrimidin thia$

hydroxyethyl)amino]-1-propanol

MS: APCI (+ve) 484 (M+1)

 $(\pm) - 1 - [2-Amino-5 - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - 3-pyrrolidinol$

5 MS: APCI (+ve) 452 (M+1)

Example 106

 $\label{lem:constraint} $$(trans)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-hydroxy-L-proline phenylmethyl ester$

10

15

MS: APCI (+ve) 586 (M+1)

Example 107

 $(\pm) -1 - [2-Amino-5 - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] -3-piperidinemethanol\\$

MS: APCI (+ve) 480 (M+1)

 $(\pm) - 1 - [2-Amino-5 - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] - 3-piperidinol$

5 MS: APCI (+ve) 466 (M+1)

Example 109

 $(2S) \hbox{-} 1-[2-Amino-5-[[(3-phenoxyphenyl)methyl] thio] thiazolo[4,5-d] pyrimidin-7-yl]-2-pyrrolidine methanol$

MS: APCI (+ve) 466 (M+1)

Example 110

 $1\hbox{-}[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio]thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]\hbox{-}4\hbox{-}4$

15 piperidinol

10

MS: APCI (+ve) 466 (M+1)

(2R) - 2 - [[2-Amino-5 - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino] - 1-butanol

(a) 7-chloro-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2-amine Prepared by the method of Example1(a).

m.p. 178-180°C

MS: APCI (+ve) 401 (M+1)

¹H NMR: δ (DMSO) 4.37 (s,2H), 6.83-7.39 (m,9H) and 8.95 (s,2H).

(b) (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol

Prepared by the method of Example 1(b).

15

20

m.p. 108-111°C

MS: APCI (+ve) 454 (M+1)

¹H NMR: δ (DMSO) 0.81 (t,3H), 1.41 (m,2H), 1.62 (m,2H), 3.36 (m,2H), 4.03 (m,1H),

4.31 (q,2H), 4.62 (s,1H), 6.78-7.38 (m,9H) and 8.00 (s,2H).

(2S) - 2 - [[2-Amino-5 - [[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino] - 1-butanol

5 Prepared by the method of Example 1(b).

m.p. 111-114°C

MS: APCI (+ve) 454 (M+1)

¹H NMR: δ (DMSO) 0.81 (t,3H), 1.41 (m,2H), 1.62 (m,2H), 3.36 (m,2H), 4.02 (br d,1H),

4.32 (q,2H), 4.60 (s,1H), 6.79-7.40 (m,9H) and 8.04 (s,2H).

Example 113

(2R) - 2 - [[2-Amino-5-[[(2,3-difluor ophenyl)methyl]thio]thiazolo[4,5-d] pyrimidin-7-yl] amino] - 1-butanol

15

10

(a) 7-Chloro-5-[[(3,4-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2-amine Prepared by the method of Example 1(a) using the product of Example 3.

m.p. 209-210°C

20 MS: APCI(+ve) 345/6 (M+1)

¹H NMR: δ (DMSO) 4.45 (s,2H), 7.10-7.42 (m,3H) and 8.90 (br s,2H).

(b) (2R)-2-[[2-Amino-5-[[(3,4-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol

Prepared by the method of Example 1(b) using the product of step a) above.

MS: APCI(+ve) 398 (M+1)

H NMR: δ (DMSO) 0.82 (t,3H), 1.34-1.71 (m,4H), 3.37 (m,2H), 4.03 (br d,1H), 4.38 (q,2H), 4.62 (t,1H), 6.96 (d,1H), 7.06-7.40 (m,3H) and 8.02 (s,2H).

Example 114

2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,3-propanediol

Prepared by the method of Example 1(b).

15 m.p. 220-222°C

MS: APCI (+ve) 456 (M+1)

 1 H NMR: δ (DMSO) 3.50 (t,4H), 4.13 (m,1H), 4.32 (s,2H), 4.60 (t,2H), 6.78-7.40 (m,10H) and 8.01 (s,2H).

Example 115

 $\hbox{$2$-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol}$

Prepared by the method of Example 1(b) with 10 equivalents of amine, 45-65°C and reaction time of 3 weeks. Purification by chromatography on silica eluting with methanol/dichloromethane mixtures gave the title compound.

5 m.p. 126-130°C

MS: APCI (+ve) 454 (M+1)

¹H NMR: δ (DMSO) 1.30 (s,6H), 3.53 (d,2H), 4.33 (s,2H), 4.86 (t,1H), 6.28 (s,1H), 6.80-7.40 (m,9H) and 8.00 (s,2H).

Example 116

 $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(2,3\hbox{-}difluor ophenyl)methyl]thio]thiazolo[4,5\hbox{-}d]pyrimidin-7-yl]amino]-2\hbox{-}methyl-1\hbox{-}propanol}$

Prepared by the method of Example 1(b) using the product of Example 113, step a), 10 equivalents of amine, 45-65°C and reaction time of 3 weeks. Purification by chromatography on silica eluting with methanol/dichloromethane mixtures gave the title compound.

m.p. 231-234°C

15

20 MS: APCI (+ve) 398 (M+1)

 1 H NMR: δ (DMSO) 1.30 (s,6H), 3.53 (d,2H), 4.40 (s,2H), 4.84 (t,1H), 6.32 (s,1H), 7.10-7.40 (m,3H) and 8.03 (s,2H).

1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-2-propanol

The product from Example 113, step a) (0.1g) and 1-amino-2-methyl-propan-2-ol (0.5g) in tetrahydrofuran (10ml) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) to afford the title compound (0.051g).

MS (APCI) 398 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 8.05 (2H, s), 7.39-7.17 (2H, m), 7.16-7.05 (2H, m), 4.51 (1H, s), 5.23 (1H, d), 4.39 (2H, s), 3.37 (2H, d), 1.06 (6H, s).

15 **Example 118**

10

20

 $5-[[(2,3-\text{Difluorophenyl})\text{methyl}]\text{thio}]-N^7-(2-\text{fluoroethyl})\text{thiazolo}[4,5-d]$ pyrimidine-2,7-diamine

The product from Example 113, step a) (0.1g), 2-fluoroethylamine hydrochloride (0.5g) and *N*,*N*-ethyldiisopropylamine (0.4ml) in tetrahydrofuran:water (7ml, 5:2) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) to afford the title compound (0.027g).

25 MS (APCI) 372 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 8.09 (2H, s), 7.36 (1H, t), 7.38-7.10 (3H, m), 4.57 (1H, t), 4.21 (3H,m), 3.71 (1H, q), 4.39 (2H, s), 3.63 (1H, q).

 $(\textit{IR-trans}) \ 2 - [[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclopentanol$

The product from example 113 step a) (0.2g), (1R,2R) 2-aminocyclopentanol hydrochloride (1.0g) and N-ethyldiisopropylamine (1.2ml) in methanol (15ml) was heated in a sealed vessel at 120 °C for 90 mins. The mixture was evaporated to dryness and purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) to afford the title compound (0.098g).

10

MS (APCI) 410 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 8.04 (2H, s), 7.41-7.27 (2H, m), 7.20 (1H, d), 7.16-7.11 (1H, m), 4.76 (1H, d), 4.41 (2H, dd), 4.09 (1H, m), 3.95 (1H, m), 1.99 (1H, m), 1.89 (1H, m), 1.62 (2H, m), 1.49-1.36 (2H, m).

15

Example 120

(*IS-trans*) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclopentanol

20 Prepared by the method of Example 119 using the product from Example 113, step a) and (1S,2S)-2-aminocyclopentanol hydrochloride.

MS (APCI) 410 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 8.03 (2H, s), 7.41-7.27 (2H, m), 7.20 (1H, d), 7.16-7.11 (1H, m),

²⁵ 4.76 (1H, d), 4.41 (2H, dd), 4.09 (1H, m), 3.96 (1H, m), 1.99 (1H, m), 1.89 (1H, m), 1.62 (2H, m), 1.49-1.36 (2H, m).

 $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino]-2\hbox{-}methyl-1\hbox{-}propanol$

Prepared by the method of Example 117 using the product of Example 1, step a) (0.6g) and 2-amino-2-methyl-propanol. Purification (SiO₂, ethyl acetate as eluant) gave the title compound (0.46g).

MS (APCI) $362 (M+H^+, 100\%)$.

NMR δH (d₆-DMSO) 8.00 (2H, s), 7.42-7.20 (5H, m), 6.29 (1H, s), 4.86 (1H, s), 4.35 (2H, s), 3.56 (2H, d), 1.32 (6H, s).

Example 122

15

2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

- a) 2-[[2-Bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol
- To a solution of the product from Example 121 (0.1g) in bromoform (5 ml) was added isoamylnitrite (0.13 ml) and the mixture heated at 60°C for 10 mins. The mixture was evaporated to dryness then purified (SiO₂, ethyl acetate: dichloromethane 1:9 as eluant) to give the subtitle compound (0.043g).
- 25 MS (APCI) 426 (M+H⁺, 100%).
 - b) 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

To a solution of the product from step a) (0.043g) in methanol (5ml) was added a saturated solution of methanolic methylamine (20ml) and the mixture strirred for 30 mins. The mixture was evaporated to dryness and purified (HPLC, Novapak®C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 70:30 over 15 minutes) to afford the title compound (0.026g).

MS (APCI) 376 (M+H⁺, 100%). NMR δH (d₆-DMSO) 8.49 (1H, d), 7.42-7.21 (5H, m), 6.34 (1H, s), 4.87 (1H, s), 4.35 (2H, s), 3.56 (2H, d), 2.94 (3H, d), 1.33 (6H, s).

Example 123

5

10

20

25

2-[[2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

a) 2-[[2-Bromo-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

The sub-title compound was prepared by the method of Example 122, step a) using the product from Example 116. Purification (SiO₂, ethyl acetate: dichloromethane 1:9 as eluant) gave the subtitle compound (0.16g).

MS (APCI) 461 (M+H⁺, 100%).

b)2-[[2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

Prepared by the method of Example 122, step b) using the product from step a). Purification (SiO₂, ethyl acetate: dichloromethane 1:9 as eluant) gave the title compound (0.051g).

MS (APCI) 488 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.08(1H, d), 7.38-7.12 (8H, m), 6.42 (1H, s), 4.82 (1H, t), 4.59 (2H, s), 4.42 (2H, s), 3.54 (2H, d), 1.29 (6H, s).

5 Example 124

10

15

20

25

5-[[(2,3-Difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

To a solution of the product from Example 3 (1.0g) in tetrahydrofuran (50ml) was added isoamyl nitrite (3ml) and the mixture heated at 70°C for 2 hours. The mixture was evaporated to dryness and purified (SiO₂, ethyl acetate: chloroform 1:9 as eluant) to give the title compound (0.61g).

MS (APCI) 512 (M+ H^+ , 100%).

NMR δH (d₆-DMSO) 13.19(1H, s), 9.61(1H, d), 7.44-7.33 (2H, m), 7.22-15 (1H, m), 4.59 (2H, s).

Example 125-148

Example 125 to 148 were prepared by heating, the product of Example 113, step a) $(5x10^{-6}$ moles) with the appropriate amine (10 equivalents) and *N*-ethyldiisopropylamine (20 equivalents) in *N*-methylpyrrolidinone (0.3 ml) in a sealed vessel at 120°C for 16 hours.

Example 125

(±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol

MS (APCI) 398 (M+H⁺, 100%).

(1S,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclohexanol

5 MS (APCI) 424 (M+H⁺, 100%).

Example 127

10

15

 $\label{thm:condition} (\pm) -2 - [[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino] -1 - propanol$

MS (APCI) 384 (M+H⁺, 100%)

Example 128

2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol

MS (APCI) 370 ($M+H^+$, 100%).

Example 129

20 (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

MS (APCI) 426 (M+H⁺, 100%).

Example 130

 $\label{lem:condition} $$(\pm)-1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol$

MS (APCI) 384 (M+H⁺, 100%).

2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1,3-propanediol

5 MS (APCI) 414 (M+H⁺, 100%).

Example 132

1-[[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-cyclohexanol

MS (APCI) 438 (M+H⁺, 100%).

Example 133

10

15

(2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol

MS (APCI) 398 (M+H⁺, 100%).

Example 134

2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-(2-aminoethyl)amino]-1-ethanol

MS (APCI) 413 (M+H⁺, 100%).

Example 135

2-[2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]-1-ethanol

MS (APCI) 414 (M+H⁺, 100%).

 (αS) - α -[(1R)-1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]ethyl]-benzenemethanol

5 MS (APCI) 474 (M+H⁺, 100%).

Example 137

10

15

20

30

 ${\bf 1\hbox{-}[2\hbox{-}Amino\hbox{-}5\hbox{-}[[(2,3\hbox{-}difluor ophenyl)methyl]} thio] thiazolo[4,5\hbox{-}d] pyrimidin\hbox{-}7\hbox{-}yl]\hbox{-}4-piperidinol}$

MS (APCI) 410 (M+H⁺, 100%).

Example 138

 $5-[[(2,3-Difluorophenyl)methyl]thio]-N^7-ethyl-thiazolo[4,5-d]pyrimidine-2,7-diamine$

MS (APCI) 354 (M+H⁺, 100%).

Example 139

 $5-[[(2,3-\text{Difluorophenyl})\text{methyl}]\text{thio}]-N^7-(2-\text{propenyl})-\text{thiazolo}[4,5-d]$ pyrimidine-2,7-diamine

MS (APCI) 366 (M+H⁺, 100%).

Example 140

25 2-Bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one

To a solution of the product from Example 9 (2g) in bromoform (100ml) was added isoamyl nitrite (2ml) and the mixture heated at 80°C for 2 hour. The mixture was evaporated to dryness and purified (SiO₂, dichloromethane as eluant) to give the title compound (0.76g).

MS (APCI) 355, 354 (M+H $^+$), 354 (100%).

Example 141

5 (1S,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-phenyl-1,3-propanediol

MS (APCI) 476 (M+H⁺, 100%).

10 **Example 142**

2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,3-propanediol

MS (APCI) 400 (M+H⁺, 100%).

Example 143

15

25

2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol

20 MS (APCI) 370 (M+H⁺, 100%).

Example 144

(\pm)-5-[[(2,3-Difluorophenyl)methyl]thio]- N^7 -(2-methoxy-1-methylethyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine

MS (APCI) 398 (M+H⁺, 100%).

Example 145

 $N^7\text{-}Cyclopropyl-5\text{-}[[(2,3\text{-}difluorophenyl)methyl]thio]-thiazolo[4,5\text{-}d]pyrimidine-2,7\text{-}difluorophenyl]}$

30 diamine

MS (APCI) 366 (M+H⁺, 100%).

Example 146

 (\pm) -2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 384 (M+H⁺, 100%).

10 Example 147

 $\begin{tabular}{l} 4-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol \end{tabular}$

MS (APCI) 398 (M+H+, 100%).

Example 148

15

25

5- $[(2,3-Difluorophenyl)methyl]thio]-N^7-[2-(1H-imidazol-4-yl)ethyl]-thiazolo[4,5-d]pyrimidine-2,7-diamine$

20 MS (APCI) 420 (M+H⁺, 100%).

Example 149-165

The compounds of Example 149 to 165 were prepared by heating 2-[[2-bromo-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol (prepared according to the method of Example 122, step a) using the product of Example 116) (5x10⁻⁶ moles) with the appropriate amine (2 equivalents) and *N*-ethyldiisopropylamine (2 equivalents) in tetrahydrofuran (0.5 ml) at 50-60°C for 16 hours.

N-[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]-serine, methyl ester

MS (APCI) $500 (M+H^+, 100\%)$.

Example 150

 $2\hbox{-}[[5\hbox{-}[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}2\hbox{-}[(1\hbox{-}methylethyl)amino}]\hbox{thiazolo}[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 440 (M+H⁺, 100%).

Example 151

10

15

 $2\hbox{-}[[5\hbox{-}[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}2\hbox{-}(ethylamino)thiazolo[4,5\hbox{-}d]pyrimidin-7-yl]amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 426 (M+H⁺, 100%).

Example 152

2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 541 (M+H⁺, 100%).

Example 153

2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

30 MS (APCI) 538 ($M+H^+$, 100%).

 $2\hbox{-}[[5\hbox{-}[[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}2\hbox{-}[(1,2\hbox{-}diphenylethyl)amino}]\hbox{thiazolo}[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]\hbox{amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 578 (M+H⁺, 100%).

Example 155

2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 480 (M+H⁺, 100%).

Example 156

2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 578 (M+H⁺, 100%).

20

5

10

Example 157

 $2\hbox{-}[[5\hbox{-}[[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}2\hbox{-}[(1,1\hbox{-}dimethylethyl)amino}]\hbox{-}thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

25 MS (APCI) 454 (M+H⁺, 100%).

Example 158

 $2\hbox{-}[[5\hbox{-}[[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}2\hbox{-}[[2\hbox{-}(2\hbox{-}thienyl)ethyl]amino}]\hbox{thiazolo}[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 508 (M+H⁺, 100%).

Example 159

2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-

d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 494 (M+H⁺, 100%).

Example 160

2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide

MS (APCI) 455 (M+H⁺, 100%).

15 **Example 161**

 $\label{lem:condition} 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol$

20 MS (APCI) 517 (M+H⁺, 100%).

Example 162

25

 $2\hbox{-}[[5\hbox{-}[[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}2\hbox{-}[(2\hbox{-}fluor oethyl)amino}]\hbox{thiazolo}[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]\hbox{amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 444 (M+H⁺, 100%).

Example 163

30 d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 438 (M+H⁺, 100%).

Example 164

5 (±)-2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol

MS (APCI) 484 (M+H⁺, 100%).

10 Example 165

 $2\hbox{-}[[5\hbox{-}[[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}2\hbox{-}[[2\hbox{-}(2\hbox{-}hydroxyethoxy)ethyl]amino}]\hbox{-}thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

15 MS (APCI) 486 (M+H⁺, 100%).

Example 166

- 2-Bromo-5-[[(2,3-difluor ophenyl)methyl]thio]-thiazolo[4,5-d] pyrimidin-7(4H)-one
- To a solution of the product from Example 3 (0.2g) in bromoform (5ml) was added isoamyl nitrite (0.25ml) and the mixture heated at 70°C for 1 hour. The mixture was evaporated to dryness and purified (SiO₂, dichloromethane as eluant) to give the title compound (0.08g).
- 25 NMR δ H (d₆-DMSO) 7.42-7.14 (3H, m), 4.55 (2H, s).

Example 167-173

The compounds of Example 167 to 173 were prepared by heating, the product of Example 166 with the appropriate amine (1.2 equivalents) and *N*-ethyldiisopropylamine (0.1ml) in tetrahydrofuran (0.2 ml) at 40°C for 16 hours.

Example 167

 $N\hbox{-}[5\hbox{-}[[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}6,7\hbox{-}dihydro\hbox{-}7\hbox{-}oxo\hbox{-}thiazolo}[4,5\hbox{-}d]pyrimidin-2-yl]\hbox{-}DL-serine, methyl ester}$

MS (APCI) 429 (M+H⁺, 100%).

Example 168

10

 $5\hbox{-}[[(2, 3\hbox{-}Difluor ophenyl) methyl] thio]\hbox{-}2\hbox{-}[(1\hbox{-}methylethyl) amino]\hbox{-}thiazolo[4, 5\hbox{-}1] thio]\hbox{-}2\hbox{-}[(1, 3\hbox{-}Difluor ophenyl) methyl] thio]$

d]pyrimidin-7(4H)-one

MS (APCI) 369 (M+H⁺, 100%).

Example 169

5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]-thiazolo[4,5-d]pyrimidin-7(4*H*)-one.

MS (APCI) 470 (M+ H^+ , 100%).

25 **Example 170**

 $2\hbox{-}[[5\hbox{-}[[(2,3\hbox{-}Difluor ophenyl)methyl]thio}]\hbox{-}6,7\hbox{-}dihydro\hbox{-}7\hbox{-}oxo\hbox{-}thiazolo}[4,5\hbox{-}d]pyrimidin-2\hbox{-}yl]amino}]\hbox{-}acetamide$

MS (APCI) 384 (M+H⁺, 100%).

 $2\hbox{-}[[2\hbox{-}(4\hbox{-}Aminophenyl)ethyl]amino]\hbox{-}5\hbox{-}[[(2\hbox{,}3\hbox{-}difluorophenyl)methyl]thio]\hbox{-}thiazolo[4\hbox{,}5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$

5 MS (APCI) 446 (M+H⁺, 100%).

Example 172

 $5\hbox{-}[[(2,\!3\hbox{-}Difluor ophenyl)methyl]thio]-2\hbox{-}[(2\hbox{-}fluor oethyl)amino]-thiazolo[4,\!5\hbox{-}d] pyrimidin-7(4H)-one$

MS (APCI) 373 (M+H⁺, 100%).

Example 173

10

15

20

5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one

MS (APCI) 415 (M+H⁺, 100%).

Example 174-218

Example 174 to 218 were prepared by heating the product of Example 122, step a) $(5x10^{-6}$ moles) with the appropriate amine (2 equivalents) and *N*-ethyldiisopropylamine (2 equivalents) in *N*-methylpyrrolidinone (0.1 ml) in a sealed vessel at 60°C for 5 hours.

Example 174

 $2\hbox{-}[[2\hbox{-}(Cyclohexylamino)\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 444 (M+H+, 100%).

2-[[2-[(1,1-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d] pyrimidin-7-yl] amino]-2-methyl-1-propanol

5 MS (APCI) 418 (M+H⁺, 100%).

Example 176

N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-DL-alanine, methyl ester

MS (APCI) 448 (M+H⁺, 100%).

Example 177

10

15

4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-cyclohexanol

MS (APCI) 460 (M+H⁺, 100%).

Example 178

2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 494 (M+H⁺, 100%).

25 **Example 179**

MS (APCI) 446 (M+H⁺, 100%).

2-Methyl-2-[[2-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 404 (M+H⁺, 100%).

Example 181

 $2\hbox{-}[[2\hbox{-}(4\hbox{-}Aminophenyl)ethyl]amino]-5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino]-2\hbox{-}methyl-1\hbox{-}propanol }$

MS (APCI) 481 (M+H⁺, 100%).

Example 182

10

15

N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-L-valine, ethyl ester

MS (APCI) 490 (M+H⁺, 100%).

Example 183

(2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-4-methyl-pentanamide.

MS (APCI) 475 (M+H⁺, 100%).

Example 184

2- Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d] pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 466 (M+H⁺, 100%).

 $2\hbox{-}[[2\hbox{-}[[(4\hbox{-}Aminophenyl)methyl]amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

 5 MS (APCI) 467 (M+H⁺, 100%).

Example 186

2- Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 472 (M+H⁺, 100%).

Example 187

10

15

 $2\hbox{-}[[2\hbox{-}[(2\hbox{-}Fluoroethyl)amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo[4,5-d] pyrimidin-7-yl] amino]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 408 (M+H⁺, 100%).

Example 188

2-Methyl-2-[[2-[[(3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 497 (M+H⁺, 100%).

Example 189

 $(\alpha R)-\alpha-[(1S)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-\\[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenemethanol$

MS (APCI) 496 (M+H⁺, 100%).

2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 542 (M+H⁺, 100%).

Example 191

 $2-Methyl-2-[[2-[(1R-trans)-(2-phenylcyclopropyl)amino]-5-\\ [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol$

MS (APCI) 478 (M+H⁺, 100%).

Example 192

10

15

2-[[2-[[2-(1*H*-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 505 (M+H⁺, 100%).

Example 193

2-[[2-[(1,1-Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 432 (M+H⁺, 100%).

25 **Example 194**

(±)-2-Methyl-2-[[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) $432 (M+H^+, 100\%)$.

(\pm)-2-Methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 460 (M+H⁺, 100%).

Example 196

2-[[2-[[(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 467 (M+H⁺, 100%).

Example 197

10

15

2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1,3-propanediol

MS (APCI) 436 (M+H⁺, 100%).

Example 198

2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 450 (M+H⁺, 100%).

Example 199

(2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-3,3-dimethyl-1-butanol

MS (APCI) 462 (M+H⁺, 100%).

 (αS) - α -[(1R)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-2-methoxyethyl]-benzenemethanol

MS (APCI) 526 (M+H⁺, 100%).

Example 201

5

10

2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 390 (M+H⁺, 100%).

Example 202

2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 538 (M+H⁺, 100%).

20 Example 203

 $\label{lem:conditional} $$(\pm)-2-Methyl-2-[[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol$

MS (APCI) 418 (M+H⁺, 100%).

Example 204

25

 $2\hbox{-}[[2\hbox{-}[[(4\hbox{-}Methoxyphenyl)methyl]amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}]\hbox{thiazolo}[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]\hbox{amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

30 MS (APCI) 482 (M+H⁺, 100%).

 $2\hbox{-}[[2\hbox{-}[(2\hbox{-}Hydroxyethyl)amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7-yl] amino]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

MS (APCI) 406 (M+H⁺, 100%).

Example 206

5

 $2\hbox{-}[[2\hbox{-}(1H\hbox{-}Imidazol\hbox{-}4\hbox{-}yl)ethyl]amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}4]$

10 d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 456 (M+H⁺, 100%).

Example 207

2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 528 (M+ H^+ , 100%).

Example 208

(2S) - 2 - [[7 - [(2 - Hydroxy - 1, 1 - dimethylethyl) amino] - 5 - [(phenylmethyl)thio] thiazolo[4, 5 - d] pyrimidin - 2 - yl] amino] - 1 - butanol

MS (APCI) 434 (M+H⁺, 100%).

Example 209

25

 $2\hbox{-}[[2\hbox{-}[(2,2\hbox{-}Diethoxyethyl)amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7-yl] amino]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

30 MS (APCI) 478 (M+H⁺, 100%).

 $\begin{tabular}{l} 4-[[7-[(2-Hydroxy-1,1-dimethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-butanol \end{tabular}$

MS (APCI) 434 (M+H⁺, 100%).

Example 211

5

(1S,2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-cyclohexanol.

MS (APCI) 460 (M+H⁺, 100%).

Example 212

(±)-2-[[2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 420 (M+ H^+ , 100%).

20 **Example 213**

2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 450 (M+H⁺, 100%).

Example 214

25

(\pm)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol

30 MS (APCI) 448 (M+H⁺, 100%).

 $2\hbox{-}[[7\hbox{-}[(2\hbox{-}Hydroxy\hbox{-}1,1\hbox{-}dimethylethyl)amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo[4,5\hbox{-}d] pyrimidin-2\hbox{-}yl] amino}]\hbox{-}acetamide$

MS (APCI) 419 (M+H⁺, 100%).

Example 216

5

(±)-2-[[2-[[1-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5d]pyrimidin-7-yl]amino]-2-methyl-propanol

MS (APCI) 484 (M+H⁺, 100%).

Example 217

(1R,2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-cyclohexanol

MS (APCI) 460 (M+H⁺, 100%).

Example 218

 $(\alpha S)-\alpha-[(1R)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-\\[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenemethanol$

MS (APCI) 496 (M+H⁺, 100%).

Example 219

25

30

${\bf 2\text{-}Bromo\text{-}7\text{-}chloro\text{-}5\text{-}[(phenylmethyl)thio]\text{-}thiazolo[4,5\text{-}d]pyrimidine}$

To a solution of the product from Example 1, step a) (10g) in bromoform (300ml) was added t-butylnitrite (10ml) and the mixture heated at 60°C for 30 mins. The mixture was

evaporated to dryness then purified (SiO₂, isohexane: dichloromethane 1:1 as eluant) to give the title compound (7.5g).

MS (APCI) 373 (M+H⁺, 100%).

5 NMR δH (d₆-DMSO) 7.47-7.24 (5H, m), 4.49 (2H, s).

Example 220

7- Chloro-N-methyl-5-[(phenylmethyl) thio]-thiazolo[4,5-d] pyrimidin-2-amine

A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing methylamine (2.0 molar in THF:0.81ml) was stirred for 16 hours. The mixture was evaporated to dryness then purified (SiO₂, ethyl acetate:dichloromethane 1:9 as eluant) to give the title compound (295mg).

MS (APCI) 323 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 9.30 (1H, s), 7.46-7.22 (5H, m), 4.40 (2H, s), 3.05 (3H, s).

Example 221-223

Examples 221 to 223 were prepared by heating the product of Example 220 (2.5x10⁻⁶ moles) with the appropriate amine (2 equivalents) and *N*-ethyldiisopropylamine (3 equivalents) in *N*-methylpyrrolidinone (0.1ml) in a sealed vessel at 100°C for 10 hours.

Example 221

 (\pm) -2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 362 (M+H⁺, 100%).

(2R) - 4 - Methyl - 2 - [[2 - (methylamino) - 5 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin - 7 - yl]amino] - 1 - pentanol

5 MS (APCI) 404 (M+H⁺, 100%).

Example 223

 $N\hbox{-}[2\hbox{-}(Methylamino)\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]\hbox{-}L-serine, ethyl ester}$

MS (APCI) 420 (M+H⁺, 100%).

Example 224

10

15

25

7-Chloro-5-[(phenylmethyl)thio]-N-[(tetrahydro-2-furanyl)methyl]-thiazolo[4,5-d]pyrimidin-2-amine

Prepared according to the method of Example 220 using the product of Example 219 and tetrahydrofurfurylamine.

20 MS (APCI) 393 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 9.50 (1H, s), 7.47-7.19 (5H, m), 4.39 (2H, s), 4.06 (1H, m) 3.82 (1H, m), 3.66 (2H, m), 3.50 (1H, m), 2.00-1.53 (4H, m).

Examples 225-228

Examples 225-228 were prepared by the method of Example 221, using the product of Example 224.

 $\label{lem:condition} $$(\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol$

 $MS (APCI) 446 (M+H^+, 100\%).$

Examples 226

 $\label{lem:condition} $$(\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol$

MS (APCI) 432 (M+H⁺, 100%).

Examples 227

10

(2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-

15 furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol

MS (APCI) $474 \text{ (M+H}^+, 100\%)$.

Examples 228

N-[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester

MS (APCI) 490 (M+H⁺, 100%).

25 **Example 229**

30

 $2\hbox{-}[2\hbox{-}[[7\hbox{-}Chloro-5\hbox{-}[(phenylmethyl)thio]thiazolo}[4,5\hbox{-}d]pyrimidin-2\hbox{-}yl]amino]ethoxy]-1-ethanol \\$

Prepared according to the method of Example 220 using the product of Example 219 (0.3g) and 2-(2-aminoethoxy)ethanol.

MS (APCI) 397 (M+H⁺, 100%).

Example 230

(\pm)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

Prepared by the method of Example 221, using the product of Example 229.

10 MS (APCI) 436 (M+H⁺, 100%).

Example 231

15

20

 $\label{lem:condition} \begin{tabular}{l} 4-[2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl] benzenesulfonamide \end{tabular}$

A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing 4-(2-aminoethyl)benzenesulfonamide (0.161 g) and N-ethyldiisopropylamine (0.5 ml) was stirred for 16 hours. The mixture was evaporated to dryness then purified (SiO₂, ethyl acetate:dichloromethane 4:6 as eluant) to give the title compound (310mg).

MS (APCI) 492 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 9.45 (1H, s), 7.78-7.23 (9H, m), 4.41 (2H, s), 3.77 (2H, s) 3.02 (2H, t).

25 Examples 232-235

Examples 232-235 were prepared by the method of Example 221, using the product of Example 231.

PCT/SE99/01333

105

Example 232

 (\pm) -4-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide

5 MS (APCI) 545 (M+H⁺, 100%).

Example 233

10

 (\pm) -4-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide

MS (APCI) 531 (M+H⁺, 100%).

Example 234

4-[2-[[7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide.

MS (APCI) 573 (M+H⁺, 100%).

Example 235

20 (±)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide

MS (APCI) 531 (M+H⁺, 100%).

Example 236

30

7-Chloro-N-[2-(1H-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]- thiazolo[4,5-d]pyrimidin-2-amine

Prepared according to the method of Example 231 using the product of Example 219 and histamine.

MS (APCI) 403 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 11.86 (1H, s), 9.42 (1H, s), 7.56 (1H, s), 7.56-7.23 (5H, m), 6.87 (1H, s), 4.41 (2H, s) 3.73 (2H, m), 2.85 (2H,t).

5

Examples 237-248

Examples 237-248 were prepared by the method of Example 221, using the product of Example 236.

10

Example 237

 $N^7 - Ethyl - N^2 - [2 - (1H-imidazol-4-yl)ethyl] - 5 - [(phenylmethyl)thiothiazolo[4,5-yl)ethyl] - 5 - [(phenylmethyl)thiothiazolo[4,5-yl)ethylleth$ d]pyrimidine-2,7-diamine

15

MS (APCI) $412 (M+H^+, 100\%)$.

Example 238

 $N^2\hbox{-}[2\hbox{-}(1H\hbox{-}\mathrm{Imidazol}\hbox{-}4\hbox{-}\mathrm{yl})ethyl]\hbox{-}5\hbox{-}[(phenylmethyl)thio}]\hbox{-}N^7\hbox{-}(3\hbox{-}pyridinylmethyl)\hbox{-}100\text{-}$ thiazolo[4,5-d]pyrimidine-2,7-diamine

20

MS (APCI) 475 (M+H⁺, 100%).

Example 239

 $(\pm) - 2 - [[2 - ([2 - (1H-Imidazol-4-yl)ethyl]amino] - 5 - [(phenylmethyl)thio]thiazolo[4,5-yl)ethyl]amino] - 5 - [(phenylmethyl)thiazolo[4,5-yl)ethyl]amino] - 5 - [(phenylmethyl)thiazolo[4,5-yl)ethyl]amino[4,5-yl)ethyl]amino[4,5-yl)ethyl]amino[4,5-yl)ethyl]amino[4,5-yl)ethylaet$ d]pyrimidin-7-yl]amino]- 1-butanol

MS (APCI) 456 (M+H⁺, 100%).

Example 240

 (\pm) -2-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-propanol

5 MS (APCI) 442 (M+H⁺, 100%).

Example 241

(2R) - 2 - [[2 - (1H - Imidazol - 4 - yl)ethyl] amino] - 5 - [(phenylmethyl)thio]thiazolo[4, 5 - d]pyrimidin - 7 - yl]amino] - 4 - methyl - 1 - pentanol

MS (APCI) 484 (M+H⁺, 100%).

Example 242

10

15

(\pm)-1-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol

MS (APCI) 442 (M+H⁺, 100%).

Example 243

5-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol

MS (APCI) 470 (M+H⁺, 100%).

Example 244

1-[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol

MS (APCI) 558 (M+H⁺, 100%).

Example 245

 (\pm) -1-[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinecarboxamide

5 MS (APCI) 495 (M+H⁺, 100%).

Example 246

2-[Ethyl[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol

MS (APCI) 456 (M+H⁺, 100%).

Example 247

10

15

30

 N^2 -[2-(1*H*-Imidazol-4-yl)ethyl]- N^7 , N^7 -dimethyl-5-[(phenylmethyl)thio]- thiazolo[4,5-d]pyrimidine-2,7-diamine

MS (APCI) 412 (M+H⁺, 100%).

Example 248

 N^7 -[2-(Diethylamino)ethyl]- N^7 -ethyl- N^2 -[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

MS (APCI) 511 (M+H⁺, 100%).

Example 249

7- Chloro-N-(2-phenoxyethyl)-5-[(phenylmethyl)thio]-thiazolo[4,5-d] pyrimidin-2-amine

Prepared by the method of Example 231, using the product of Example 219 and 2-phenoxyethylamine.

MS (APCI) 429 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.65 (1H, s), 7.46-6.93 (10H, m), 4.41 (2H, s), 4.20 (2H, t), 3.87 (2H, m).

5

Examples 250-255

Examples 250-255 were prepared by the method of Example 221, using the product of Example 249.

10

Example 250

 N^2 -(2-Phenoxyethyl)-5-[(phenylmethyl)thio]- N^7 -(3-pyridinylmethyl)-thiazolo[4,5d]pyrimidine-2,7-diamine

15

MS (APCI) 501 (M+H⁺, 100%).

Example 251

 $N^2 - (2-Phenoxyethyl) - N^7 - [1-(phenylmethyl) - 4-piperidinyl] - 5-[(phenylmethyl)thio] - (phenylmethyl) - (phenylmethyl$ thiazolo[4,5-d]pyrimidine-2,7-diamine

20

MS (APCI) 583 (M+H⁺, 100%).

Example 252

2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl)thio]thiazolo[4,5-methyl-2-[(2-phenylmethyl-2-[

d]pyrimidin-7-yl]amino]-1-propanol.

MS (APCI) 482 (M+H⁺, 100%).

Example 253

 $(\pm) - 2 - [[2 - [(2 - Phenoxyethyl)amino] - 5 - [(phenylmethyl)thio]thiazolo[4,5 - d]pyrimidin - 7 - yl]amino] - 1 - propanol$

5 MS (APCI) 468 (M+H⁺, 100%).

Example 254

 $(2R)\hbox{-}4\hbox{-}Methyl\hbox{-}2\hbox{-}[[2\hbox{-}[(2\hbox{-}phenoxyethyl)amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}]thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7\hbox{-}yl]amino}]\hbox{-}1\hbox{-}pentanol$

MS (APCI) 510 (M+H⁺, 100%).

Example 255

10

15

1-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol.

MS (APCI) 584 (M+H⁺, 100%).

Example 256

7-Chloro-N-cyclopropyl-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-2-amine,

Prepared by the method of Example 220, using the product of Example 219 and cyclopropanamine.

25 MS (APCI) 351, 349 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 7.46-7.22 (5H, m), 4.41 (2H, s), 2.85-2.80 (1H, m), 0.90-0.84 (2H, m), 0.71-0.66 (2H, m).

Examples 257-260

Example 257 to 260 were prepared by the method of Example 221 using the product of Example 256.

5

 $2\hbox{-}[[2\hbox{-}(Cyclopropylamino})\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo\ [4,5\hbox{-}d] pyrimidin-7-yl] amino} -1\hbox{-}butanol$

10 MS (APCI) 402 (M+H⁺, 100%).

Example 258

Example 257

 $2\hbox{-}[[2\hbox{-}(Cyclopropylamino})\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo\ [4,5\hbox{-}d] pyrimidin-7-yl] amino} -1\hbox{-}propanol$

MS (APCI) 388 (M+H⁺, 100%).

Example 259

15

 $(2R)\hbox{-}2\hbox{-}[[2\hbox{-}(Cyclopropylamino)\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo$

20 [4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

MS (APCI) 430 (M+H⁺, 100%).

Example 260

N-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester

MS (APCI) 446 (M+H⁺, 100%).

Example 261

$2\hbox{-}[[7\hbox{-}Chloro-5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-2\hbox{-}yl]amino]-1\hbox{-}pentanol$

Prepared by the method of Example 231, using the product of Example 219 and 2-amino-1-pentanol.

MS (APCI) 397, 395 (M+H $^+$, 100%). 1 H NMR (d $_6$ -DMSO) δ 9.29 (1H, s), 7.46-7.22 (5H, m), 4.93 (1H, t), 4.39 (2H, s), 4.07-4.00 (1H, m), 3.50 (2H, t), 1.63-1.43 (2H, m), 1.38-1.32 (2H, m), 0.89 (3H, t).

Examples 262-264

10

15

25

30

Example 262 to 264 were prepared by the method of Example 221 using the product of Example 261.

Example 262

(2R)-2-[[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

20 MS (APCI) 476 (M+H⁺, 100%).

Example 263

N-[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester

MS (APCI) 492 (M+H⁺, 100%).

Example 264

(±)-2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol

MS (APCI) 502 (M+H⁺, 100%).

Examples 265-270

The following examples were prepared by the method of Example 221, using the product of Example 229.

Examples 265

 $2\hbox{-}[2\hbox{-}[[7\hbox{-}(Ethylamino)\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-2-d]}$

10 yl]amino]ethoxy-1-ethanol

MS (APCI) 406 (M+H⁺, 100%).

Examples 266

2-[2-[[7-[(1-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxy]-1-ethanol

MS (APCI) 420 (M+H⁺, 100%).

20 Examples 267

 (\pm) -2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,

MS (APCI) 450 (M+H⁺, 100%).

Examples 268

25

 $2\hbox{-}[[2\hbox{-}(2\hbox{-}Hydroxyethoxy)ethyl]amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7\hbox{-}yl]amino}]\hbox{-}2\hbox{-}methyl-1\hbox{-}propanol$

30 MS (APCI) 450 (M+H⁺, 100%).

Examples 269

(2R)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,

MS (APCI) 478 (M+H⁺, 100%).

Examples 270

5

20

25

2-[Cyclohexyl-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol

MS (APCI) 504 (M+H⁺, 100%).

Examples 271

- (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol
 - a) 7-Chloro-5-[(phenylmethyl)thio]-N-(4-piperidinyl)-thiazolo[4,5-d]pyrimidin-2-amine

A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing 4-amino-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester (0.161g) and N-ethyldiisopropylamine (0.5 ml) was stirred for 16 hours before evaporating to dryness. The residue was taken into dichloromethane (30ml) and trifluoroacetic acid (3ml) added. The solution was stirred for 30 minutes then concentrated to give the title compound (310mg).

MS (APCI) 392 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 9.47 (1H, s), 8.64-8.48 (2H, s), 7.46-7.23 (5H, s), 4.41 (2H, s) 4.21

(1H, s), 3.34 (2H, m), 3.09 (2H, m), 2.18 (2H, m), 1.69 (2H, m).

- b) (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol
- 5 Prepared by the method of Example 221, using the product of step a).

MS (APCI) 431 (M+H⁺, 100%).

Example 272

N-[2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5 d]pyrimidin-2-yl]amino]ethyl]-acetamide

Prepared according to the method of Example 231 using the product of Example 219.

15 MS (APCI) 396, 394 (M+H⁺), 394 (100%).

Examples 273-276

Examples 273-276 were prepared by the method of Example 221 using the product of Example 272.

20

Example 273

- 25 MS (APCI) 447 (M+H⁺, 100%)

Examples 274

 (\pm) -N-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,

MS (APCI) 433 (M+H⁺, 100%)

Examples 275

 $N-[2-[[7-[(2-{\rm Hydroxyethyl})amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide$

MS (APCI) 419 (M+H⁺, 100%)

Example 276

N-[2-[[7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,

MS (APCI) 475 (M+H⁺, 100%)

15 **Example 277**

7- Chloro-5-[(phenylmethyl)thio]-N-[2-(2-thienyl)ethyl]-thiazolo[4,5-d] pyrimidin-2-amine

Prepared by the method of Example 231, using the product of Example 219 and 2-(2-thienyl)ethylamine.

MS (APCI), 420, 418 (M+H⁺), 418 (100%). NMR δH (d₆-DMSO) 7.45-7.32 (5H, m), 6.96 (2H, m), 4.40 (2H, s), 3.78 (2H, s), 3.16 (2H, t).

Examples 278-284

25

Examples 276 to 284 were prepared by the method of Example 221 using the product of Example 277.

Example 278

 N^7 -(2-Methoxyethyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine

5 MS (APCI) 457 (M+H⁺, 100%).

Example 279

 N^7 -(2-Ethoxyethyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine

MS (APCI) 471 (M+H⁺, 100%).

Example 280

10

15

 N^7 -(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine

MS (APCI) 469 (M+H⁺, 100%).

Example 281

(2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-pentanol

MS (APCI) 499 (M+H⁺, 100%).

Example 282

 $\label{eq:continuous} $$(\pm)-1-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol$

MS (APCI) $457 (M+H^+, 100\%)$.

Example 283

 $\label{eq:continuous} (\pm) -2 - [[5 - [(Phenylmethyl)thio] -2 - [[2 - (2 - thienyl)ethyl]amino] thiazolo[4,5 - d]pyrimidin-7 - yl]amino] -1 - butanol$

5 MS (APCI) 471 (M+H⁺, 100%).

Example 284

 (\pm) -2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-propanol

MS (APCI) 457 (M+H⁺, 100%).

Example 285

10

15

 $2\hbox{-}[[7\hbox{-}Chloro-5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-2\hbox{-}yl]amino]-1\hbox{-}ethanological and the statement of the statement$

Prepared by the method of Example 231, using the product of Example 219 and 2-aminoethanol.

MS (APCI) 355, 353 (M+H⁺), 353 (100%).

NMR δH (d₆-DMSO) 9.48 (1H, s), 7.45-7.30 (5H, m), 4.95 (1H, t), 4.40 (2H, s), 3.60 (4H, m).

Examples 286-287

Examples 286 to 287 were prepared by the method of Example 221 using the product of Example 285.

Example 286

(2R)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

MS (APCI) 433 (M+H⁺, 100%).

Example 287

 $(\pm)-N, N-Diethyl-1-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-(phenylmethyl)thiazolo[4,5-(phenylmethyl]thiazolo[4,5-(phenylme$

d]pyrimidin-7-yl]-3-piperidinecarboxamide

MS (APCI) 500 (M+H⁺, 100%).

Example 288

3-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-propanol

Prepared by the method of Example 231, using the product of Example 219 and 3-aminopropanol.

MS (APCI) 369, 367 (M+H⁺), 367 (100%).

NMR δH (d₆-DMSO) 9.36 (1H, s), 7.43-7.27 (5H, m), 4.57 (1H, t), 4.40 (2H, s), 3.49 (4H, m), 1.75 (2H, m).

Examples 289-291

Examples 289-291 were prepared by the method of Example 221 using the product of Example 288.

Example 289

(2R) - 2 - [[2 - [(3 - Hydroxypropyl)amino] - 5 - [(phenylmethyl)thio]thiazolo[4, 5 - (phenylmethyl)thio] - [(phenylmethyl)thio] - [(ph

25 d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

MS (APCI) 447 (M+H⁺, 100%).

Example 290

 $\label{eq:continuous} (\pm) -2 - [[2 - [(3 - Hydroxypropyl)amino] -5 - [(phenylmethyl)thio]thiazolo[4,5 - d]pyrimidin-7 - yl]amino] -1 - butanol$

MS (APCI) 419 (M+H⁺, 100%).

Example 291

10

15

 $\label{eq:continuous} \begin{tabular}{l} (\pm)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-$d]$ pyrimidin-7-yl]amino]-1-propanol \end{tabular}$

MS (APCI) 405 (M+H⁺, 100%)

Example 292

 $\hbox{$2$-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide}$

Prepared by the method of Example 231, using the product of Example 219 and glycinamide hydrochloride.

 $MS\ (APCI)\ 368,\ 66\ (M+H^+),\ 366\ (100\%).$

NMR δH (d₆-DMSO) 7.61 (1H, s), 7.45-7.24 (6H, m), 4.40 (2H, s), 4.14-4.12 (2H, m), 9.57 (1H, s).

Example 293

 $\hbox{$2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-methylethyl)amino]-5-[(phenylmethyl)thio]]}$

25 d]pyrimidin-2-yl]amino-acetamide

Prepared according to the method of Example 221 using the product of Example 292.

MS (APCI) 404 (M+H⁺, 100%).

PCT/SE99/01333

Example 294

 $\label{eq:continuous} \begin{tabular}{ll} 4-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-3-azetidinyl]-1-piperazinesulfonamide \end{tabular}$

Prepared by the method of Example 231, using the product of Example 219 and 3-azetidinyl-1-piperazinesulfonamide.

MS (APCI), 512, 514 (M+H⁺), 512 (100%).

NMR δH (d₆-DMSO) 7.69-7.22 (5H, m), 6.80 (2H, s), 4.40 (2H, s), 4.34-4.12 (4H, m),

3.56-3.50 (1H, m), 3.40 (4H, s), 3.00 (4H, s).

Example 295

4-[1-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-3-azetidinyl]-1-piperazinesulfonamide,

Prepared by the method of Example 221, using the product of Example 294.

MS (APCI) 588 (M+H⁺, 100%).

20 **Example 296**

7-Chloro-*N*-[[2-(4-morpholinyl)ethyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-2-amine

Prepared by the method of Example 231, using the product of Example 219 and 2-(4-morpholinyl)ethyl]amine.

MS (APCI) 424, 422 (M+H⁺), 422 (100%). NMR δH (d₆-DMSO) 9.34 (1H, s), 7.68-7.23 (5H, m), 4.40 (2H, s), 3.59-3.56 (6H, m), 2.54 (2H, t), 2.44-2.41 (4H, m).

25

Examples 297-300

Examples 297-300 were prepared according to the method of Example 221 using the product of Example 296.

5 Example 297

3-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 460 (M+H⁺, 100%).

10

Example 298

2-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

15 MS (APCI) 464 (M+H⁺, 100%).

Example 299

 $\label{lem:condition} $$(\pm)-2-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol$

20

MS (APCI) 460 (M+H⁺, 100%).

Example 300

(2R)-4-Methyl-2-[[2-[2-(4-morpholinyl)ethyl]amino]-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol

MS (APCI) 502 (M+H⁺, 100%).

Examples 301-302

Examples 301-302 were prepared by the method of Example 12 using the product of Example 140.

5 Example 301

 $2\hbox{-}[[2\hbox{-}(3,4\hbox{-}Dihydroxyphenyl)ethyl]amino}]\hbox{-}5\hbox{-}[(phenylmethyl)thio}]\hbox{-}thiazolo[4,5\hbox{-}d]pyrimidin\hbox{-}7(4H)\hbox{-}one$

MS (APCI) 427 (M+H⁺, 100%).

10

20

25

30

Example 302

(\pm)-2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-7(4H)-one

15 MS (APCI) 349 (M+H⁺, 100%).

Pharmacological Data

Ligand Binding Assay

[125]IIL-8 (human, recombinant) was purchased from Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee *et al.* (1992) *J. Biol. Chem.* 267 pp16283-16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript (Stratagene) and clones were identified using DNA. The coding sequence was sub-cloned into the eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was prepared using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate-buffered saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and centrifuged (200g, 5min.). The cell pellet was resuspended in ice cold homogenisation

WO 00/09511 PCT/SE99/01333

124

buffer [10mM HEPES (pH 7.4), 1mM dithiothreitol, 1mM EDTA and a panel of protease inhibitors (1mM phenyl methyl sulphonyl fluoride, $2\mu g/ml$ soybean trypsin inhibitor, 3mM benzamidine, $0.5\mu g/ml$ leupeptin and $100\mu g/ml$ bacitracin)] and the cells left to swell for 10 minutes. The cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, $4^{\circ}C$). The membrane preparation was stored at $-70^{\circ}C$ in homogenisation buffer supplemented with Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH₂PO₄), 0.1%(w/v) gelatin and 10%(v/v) glycerol.

All assays were performed in a 96-well MultiScreen 0.45 μ m filtration plates (Millipore, U.K.). Each assay contained ~50pM [$^{125}\Pi$ IL-8 and membranes (equivalent to ~200,000 cells) in assay buffer [Tyrode's salt solution supplemented with 10mM HEPES (pH 7.4), 1.8mM CaCl₂, 1mM MgCl₂, 0.125mg/ml bacitracin and 0.1%(w/v) gelatin]. In addition, a compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to reach a final concentration of 1%(v/v) DMSO. The assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice with assay buffer (without bacitracin). The backing plate was removed from the MultiScreen plate assembly, the filters dried at room temperature, punched out and then counted on a Cobra γ -counter.

The compounds of formula (I) according to the Examples were found to have IC $_{50}$ values of less than (<) $10\mu M$.

25 Intracellular Calcium Mobilisation Assay

Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly *et al.* (1997) Methods in Enzymology 287 pp70-72), in storage buffer [Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH₂PO₄) supplemented with 5.7mM glucose and 10mM HEPES (pH 7.4)].

10

15

10

15

The chemokine GRO α (human, recombinant) was purchased from R&D Systems (Abingdon, U.K.). All other chemicals were of analytical grade. Changes in intracellular free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt *et al.* (1990) Biochem. J. 269, pp513-519). Cells were loaded for 1 hour at 37°C in loading buffer (storage buffer with 0.1%(w/v) gelatin) containing 5 μ M fluo-3 AM ester, washed with loading buffer and then resuspended in Tyrode's salt solution supplemented with 5.7mM glucose, 0.1%(w/v) bovine serum albumin (BSA), 1.8mM CaCl₂ and 1mM MgCl₂. The cells were pipetted into black walled, clear bottom, 96 well micro plates (Costar, Boston, U.S.A.) and centrifuged (200g, 5 minutes, room temperature).

A compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A_{50} concentration of GRO α and the transient increase in fluo-3 fluorescence (λ_{Ex} =490nm and λ_{Em} = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

The compounds of formula (I) according to the Examples were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

CLAIMS

1. A compound of general formula

wherein R^1 represents a hydrogen atom, or a group $-NR^3R^4$; R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl or C_1 - C_8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_6 alkyl and trifluoromethyl groups, or R^3 and R^4 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from

-NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR¹⁰, -NR⁸COR⁹, and C₁-C₆ alkyl optionally substituted by one or more substituents independently selected from halogen atoms and -NR¹¹R¹² and -OR⁷ groups;

X represents a group -OH or -NR¹³R¹⁴;

 R^{13} and R^{14} each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C₁-C₄ alkylphenyl substituent group, or a C₃-C₇ carbocyclic, C₁-C₈ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group, which latter four groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, $-SO_2R^{10}, \ -SO_2NR^5R^6, \ -NR^8SO_2R^9, \ morpholinyl, \ C_1-C_4 \ alkyl, \ C_3-C_6 \ cycloalkyl \ and$ aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6, \; -CONR^5R^6, \; -OR^7, \; -NR^8COR^9, \; -SO_2NR^5R^6, \; NR^8SO_2R^9, \; C_1-C_6 \; alkyl \; \; and \; \; and \; \; and \; \; alkyl \; \; alkyl \; \; and \; \; alkyl \;$ trifluoromethyl groups, or R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from -NR⁵R⁶, -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , and C_1 - C_6 alkyl optionally substituted by one 15 or more substituents independently selected from halogen atoms and phenyl, -NR 11R 12 and -OR⁷ groups: R^2 represents a C_1 - C_6 alkyl or C_2 - C_6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one or more substituents independently selected from halogen atoms and nitro, 20 C_1 - C_6 alkyl, trifluoromethyl, -OR⁷, -C(O)R⁷, -SR¹⁰, -NR¹⁵R¹⁶ and phenyl groups; R^{5} and R^{6} each independently represent a hydrogen atom or a C_{1} - C_{6} alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR 17 and -NR 15R 16, or R^5 and R^6 together with the nitrogen atom to which they are attached form a 4- to 25 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, -OR 17 $-\mathsf{COOR}^{17}, \ -\mathsf{NR}^{15}\mathsf{R}^{16}, \ -\mathsf{CONR}^{15}\mathsf{R}^{16}, \ -\mathsf{NR}^{15}\mathsf{COR}^{16}, \ -\mathsf{SONR}^{15}\mathsf{R}^{16}, \ \ \mathsf{and} \ \ C_1-C_6 \ \mathsf{alkyl}$

15

20

optionally substituted by one or more substituents independently selected from halogen atoms and $-NR^{15}R^{16}$ and $-OR^{17}$ groups;

 R^7 and R^9 each independently represent a hydrogen atom or a C_1 - C_6 alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$; and each of R^8 , R^{10} , R^{11} , R^{12} , R^{15} , R^{16} and R^{17} independently represents a hydrogen atom or a C_1 - C_6 alkyl or phenyl group; with the proviso that when R^1 and X both represent $-NH_2$, then R^2 does not represent a methyl group;

or a pharmaceutically acceptable salt or solvate thereof.

- 2. A compound according to claim 1, wherein R^1 represents a group $-NR^3R^4$.
- 3. A compound according to claim 1 or claim 2, wherein R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl or C_1 - C_6 alkyl group, which latter two groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_4 alkyl and trifluoromethyl groups.
- 4. A compound according to any one of claims 1 to 3, wherein R² represents a

 C₁-C₆ alkyl or C₂-C₆ alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and nitro, C₁-C₄ alkyl, trifluoromethyl, -OR⁷, -C(O)R⁷, -SR¹⁰, -NR¹⁵R¹⁶ and phenyl.

- 5. A compound according to any one of the preceding claims, wherein X represents $-NR^{13}R^{14}$ and R^{13} and R^{14} each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C_1 - C_4 alkylphenyl substituent group, or a C₃-C₇ carbocyclic, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group, which latter four groups may be optionally substituted by one, two, three or four substituent groups 5 independently selected from halogen atoms and -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR⁷, $-NR^{8}COR^{9}, \ -SR^{10}, \ -SO_{2}R^{10}, \ -SO_{2}NR^{5}R^{6}, \ -NR^{8}SO_{2}R^{9}, \ morpholinyl, \ C_{1}-C_{4} \ alkyl,$ C₃-C₆ cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $NR^8SO_2R^9$, C_1 - C_4 alkyl and trifluoromethyl groups.
 - 6. A compound according to claim 1 being selected from:
- (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol, 15
 - (S)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - 2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 5-[[(3-Phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- (\pm) -2-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol, 20
 - 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethanol,
 - 5-(Pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one, 25
 - 2-[[2-(Diethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(3-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[[2-(Acetylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- (\pm) -2-[(2,3-Dihydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one, 30

- 2-[[2-(4-Morpholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[(1-Methylethyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
- (\pm) -2-[(2-Hydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(2-Hydroxy-2-methylpropyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[(2-Hydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - (2S,3R)-3-Hydroxy-2-[(7-oxo-5-(pentylthio)-4H-thiazolo[4,5-d]pyrimidin-2-yl]-
- 10 amino)butanamide,
 - N^7 -[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 3-[(2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-1-propanol,
- N^7 -Cyclohexyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - $\label{eq:continuous} (\pm)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-1,2-propanediol,$
 - N^7 -(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 5-(Pentylthio)- N^7 -propylthiazolo[4,5-d]pyrimidine-2,7-diamine,
- N^7 -Cyclopentyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -Cyclopropyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - $(\pm)-1-[(2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-2-propanol,\\$
 - $(\text{exo})-N^7$ -Bicyclo[2.2.1]hept-2-yl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
- 25 2-[2-[[2-Amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]ethanol,
 - $(\pm)-N^7-(2-\text{Methylbutyl})-5-(\text{pentylthio})$ thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - $1\hbox{-}[[2\hbox{-}Amino\hbox{-}5\hbox{-}(pentylthio)thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino]-2\hbox{-}methyl-2\hbox{-}propanol,}$
 - N^7 -[(2-Aminophenyl)methyl]-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- (E)-2-Amino-5-[(3-phenyl-2-propenyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,

- 2-Amino-5-[[3-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[[(4-trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3,5-dibromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-nitrophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[(2-iodophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(4-chloro-2-nitrophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl]methyl]thio]thiazolo[<math>(4,5-d)pyrimidin-(4H)-one,
 - 2-Amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-Amino-5-[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-Amino-5-[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2,2-dimethyl-1-propanol,
- (±)- α -[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]benzenemethanol,
 - (R)- β -[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]benzenepropanol,
 - 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethanol,

- (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]4-methylpentanol,
- $(\pm)-1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,$
- $(\pm)-\beta-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-pyrimidin-7-yl]amino[amino]-4-pyrimidin-7$
- 5 chlorobenzenepropanol,

- (\pm) -3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,2-propanediol,
- 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]propylamino]ethanol,
- $(\pm)-1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-pyrrolidinol,\\$
- (±)-1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinol,
 - 1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-piperidinol,
 - 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2, 2-dimethyl-1-propanol,
 - (\pm) -2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - (\pm) - α -[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-amino]methyl]benzenemethanol,
 - 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
- 6-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-hexanol,
 - 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-amino]cyclohexanol,
- (R)- β -[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]- amino]benzenepropanol,
 - (\pm) -2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5-d] pyrimidin-7-yl]-amino] ethanol, \\$

- (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-amino]-4-methylpentanol,
- $\label{lem:conditional} (\pm)-1-Amino-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,$
- (\pm) -1-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,
 - 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-2-ethyl-1,3-propanediol,
- (\pm)- β -[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol,
 - $\label{lem:conditional} (\pm) -3 [[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino] -1, 2-propanediol,$
 - 2-[[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]amino]ethanol,
- 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - (\pm) - α -[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-3,4-dichlorobenzenepropanol,
 - 1-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-2-propano!,
 - 2-[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl] amino]ethoxy]ethanol,
 - 5-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
- 25 (2S)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-(methylthio)-1-butanol,
 - 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]butylamino]ethanol,
 - $2\hbox{-}[[2\hbox{-}Amino-5\hbox{-}[[(3\hbox{-}phenoxyphenyl)methyl]thio}] thiazolo[4,5\hbox{-}d] pyrimidin-7\hbox{-}indi$
- 30 yl]propylamino]ethanol,

- 2,2'-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]imino]bisethanol,
- 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-(2-hydroxyethyl)amino]methyl]phenol,
- 5 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-(2-hydroxyethyl)amino]-1-propanol,
 - $\label{lem:condition} (\pm)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-pyrrolidinol,$
- (trans)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-hydroxy-L-proline phenylmethyl ester,
 - (\pm) -1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinemethanol,
 - $\label{eq:continuous} $$(\pm)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinol,$
- (2S)-1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-2-pyrrolidinemethanol,
 - 1-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-piperidinol,
- yl]amino]-1-butanol,
 - (2S)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
- 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,3-propanediol,
 - 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

- 1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
- $5-[[(2,3-\text{Difluorophenyl})\text{methyl}]\text{thio}]-N^7-(2-\text{fluoroethyl})\text{thiazolo}[4,5-d]$ pyrimidine-2,7-diamine,
- 5 (*IR-trans*) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclopentanol,
 - (1S-trans) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclopentanol,
 - 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 5-[[(2,3-Difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - (\pm) -2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - (1S,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-cyclohexanol,
- (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol,
 - $(2R)-2-[[2-A\min -5-[[(2,3-difluor ophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-difluor ophenyl)methyl]thiazolo[4,5-d]pyrimidin-7-difluor ophenyl]thiazolo[4,5-d]pyrimidin-7-difluor ophenyllior ophe$
- yl]amino]-4-methyl-1-pentanol,
 - $\label{eq:continuous} $$(\pm)-1-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-propanol,$
 - 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1, 3-propanediol,

- 1-[[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-cyclohexanol,
- (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
- 5 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-(2-aminoethyl)amino]-1-ethanol,
 - 2-[2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]-1-ethanol,
 - $(\alpha S) \alpha [(1R) 1 [[2 Amino 5 [[(2, 3 difluor ophenyl) methyl] thio] thiazolo [4, 5 d] pyrimidin-different and the second of the second open sec$
- 7-yl]methylamino]ethyl]-benzenemethanol,
 - 1-[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d] pyrimidin-7-yl]-4-piperidinol,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]- N^7 -ethyl-thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[(2,3-Difluorophenyl)methyl]thio]- N^7 -(2-propenyl)-thiazolo[4,5-d]pyrimidine-2,7-
- 15 diamine,

- (1*S*,2*S*)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-phenyl-1,3-propanediol,
- 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol,
- 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol,
 - (\pm)-5-[[(2,3-Difluorophenyl)methyl]thio]- N^7 -(2-methoxy-1-methylethyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^7 -Cyclopropyl-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - $\label{lem:condition} $$(\pm)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,$
 - 4-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,

- 5-[[(2,3-Difluorophenyl)methyl]thio]- N^7 -[2-(1H-imidazol-4-yl)ethyl]-thiazolo[4,5-d]pyrimidine-2,7-diamine,
- $(\pm)-N-[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]-serine, methyl ester,$
- 5 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]thiazolo[4,5-
- 10 d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,2-diphenylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[(3,4,5-
 - trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 20 ?-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[5-[[(2,3-Difluor ophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-methylcyclohexyl)amino]thiazolo[4,5-methylcyclohexyl)amino]thiazolo[4,5-methylcyclohexyl)amino]thiazolo[4,5-methylcyclohexyl)amino]thiazolo[4,5-methylcyclohexyl)amino]thiazolo[4,5-methylcyclohexyl]thiazolo[4,5-methylcycl
- 25 d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - $\hbox{$2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-hy$
 - dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide,
 - 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-
- d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[2-(Cyclopropylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 5 (±)-2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol,
 - 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-
 - hydroxyethoxy)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - N-[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-d]pyrimidin-2-
- 10 yl]-DL-serine, methyl ester,

- 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]-thiazolo[4,5-d]pyrimidin-7(4*H*)-one,
- 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1H-indol-3-yl)ethyl]amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
- 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide,
 - 2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
 - 2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[2-[(1,1-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-DL-alanine, methyl ester,
 - 4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- 30 d]pyrimidin-2-yl]amino]-cyclohexanol,

- 2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 5 2-Methyl-2-[[2-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-dimethyl]thiazolo
- od]pyrimidin-2-yl]-L-valine, ethyl ester,
 - (2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-4-methyl-pentanamide,
 - 2-Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[[(4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[(2-Fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-Methyl-2-[[2-[[(3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - (αR) - α -[(1S)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-
 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,
- 25 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(3,4,5
 - trimethoxyphenyl) methyl] amino] thiazolo [4,5-d] pyrimidin-7-yl] amino]-1-propanol,
 - 2-Methyl-2-[[2-[(1R-trans)-(2-phenylcyclopropyl)amino]-5-
 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[[2-(1H-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-left amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-left amino]-5-[(phenylmethyl)thio]-1-[(pheny
- 30 yl]amino]-2-methyl-1-propanol,

WO 00/09511 PCT/SE99/01333

- 2-[[2-[(1,1-Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- (\pm) -2-Methyl-2-[[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 5 (±)-2-Methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- 10 d]pyrimidin-2-yl]amino]-1,3-propanediol,
 - 2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - (2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-3,3-dimethyl-1-butanol,
- (αS)- α -[(1R)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-2-methoxyethyl]-benzenemethanol,
 - 2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5-
 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - (\pm)-2-Methyl-2-[[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - 2-[[2-[[(4-Methoxyphenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-amino]-5-[(phenylmethyl)thio]
- 7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

WO 00/09511 PCT/SE99/01333

- 2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7yl]amino]-2-methyl-1-propanol,
- (2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5d]pyrimidin-2-yl]amino]-1-butanol,
- 2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7yl]amino]-2-methyl-1-propanol,
 - 4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5d]pyrimidin-2-yl]amino]-1-butanol,
 - (1S,2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- d]pyrimidin-2-yl]amino]-cyclohexanol, 10
 - (\pm) -2-[[2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - 2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-partial properties of the context of the7-yl]amino]-2-methyl-1-propanol,
- $(\pm) 2 [[7 [(2 Hydroxy 1, 1 dimethylethyl) amino] 5 [(phenylmethyl)thio]thiazolo[4, 5 dimethylethyl)] 5 [(phenylmethyl)thio]thiazolo[4, 5 dimethylethyl]] 5 [(phenylmethyl)thiazolo[4, 5 dimethylethyl]] 5 [(phenylmethyll]] 5 [(phenylmethyll]]$ 15 d]pyrimidin-2-yl]amino]-1-pentanol,
 - 2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5d]pyrimidin-2-yl]amino]-acetamide,
 - (±)-2-[[2-[[1-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
- d]pyrimidin-7-yl]amino]-2-methyl-propanol, 20
 - (1R,2S)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5d]pyrimidin-2-yl]amino]-cyclohexanol,
 - (αS) - α -[(1R)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-
 - [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,
- $(\pm)-2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-d[2-(Methylamino)-1-d[2-(M$ 25 propanol,
 - (2R) 4 Methyl 2 [[2 (methylamino) 5 [(phenylmethyl)thio]thiazolo[4, 5 d]pyrimidin 7 [(phenylmethyl)thiazolo[4, 5 d]pyrimidin 7 [(phenylmethyl)thyl]amino]-1-pentanol,
- N-[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester, 30

- (\pm) -2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
- (\pm) -2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 5 (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,

 N-[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester,
 - $(\pm)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-(phenylmethyl)thiazolo[4,5-(phenylm$
- 10 d]pyrimidin-7-yl]amino]-1-propanol,
 - $\label{eq:continuous} $$(\pm)-4-[2-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,$
 - (\pm) -4-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
- 4-[2-[[7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
 - $\label{eq:continuous} $$(\pm)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,$
- N^7 -Ethyl- N^2 -[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thiothiazolo[4,5-*d*]pyrimidine-20 2,7-diamine,
 - N^2 -[2-(1*H*-Imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]- N^7 -(3-pyridinylmethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 - (\pm)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]- 1-butanol,
- (±)-2-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-propanol,
 - (2R)-2-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - $(\pm)-1-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-(phenylmethyl)thiazolo[4,5-(phenylmethyl)thio]thiazolo[4,5-(phenylmethyl)thiazolo[4,5-(phenylmethyl]thiazolo[4,5-(phenylmethyl)thiazolo[4,5-(phenylmethyl)thiazolo$
- 30 d]pyrimidin-7-yl]amino]-2-propanol,

- 5-[[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
- 1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,
- 5 (\pm) -1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinecarboxamide,
 - 2-[Ethyl[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol,
 - N^2 -[2-(1*H*-Imidazol-4-yl)ethyl]- N^7 , N^7 -dimethyl-5-[(phenylmethyl)thio]- thiazolo[4,5-
- 10 d]pyrimidine-2,7-diamine,
 - N^7 -[2-(Diethylamino)ethyl]- N^7 -ethyl- N^2 -[2-(1H-imidazol-4-yl)ethyl]-5-
 - [(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - N^2 -(2-Phenoxyethyl)-5-[(phenylmethyl)thio]- N^7 -(3-pyridinylmethyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine,
- N^2 -(2-Phenoxyethyl)- N^7 -[1-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - 2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
 - $(\pm)-2-[[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-amino[-5-[(phenylmethyl)thio]thiazolo[-6,5-d]pyrimidin-7-amin$
- 20 yl]amino]-1-propanol,
 - (\pm)-4-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
 - 1-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,
- 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - $2\hbox{-}[[2\hbox{-}(Cyclopropylamino)\hbox{-}5\hbox{-}[(phenylmethyl)thio]thiazolo[4,5\hbox{-}d]pyrimidin-7\hbox{-}yl]amino]\hbox{-}1\hbox{-}propanol,$
 - (2R)-2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-(phenylmethyl)thiazolo[4,5-d]pyrimi
- 30 yl]amino]-4-methyl-1-pentanol,

- N-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester,
- (2R)-2-[[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- N-[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-L-serine, ethyl ester,
 - (\pm) -2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-1-pentanol,
 - 2-[2-[[7-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxyl-ethanol,
 - 2-[2-[[7-[(1-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxy]-1-ethanol,
 - $\label{eq:continuous} $$(\pm)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,$
- 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
 - (2*R*)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - 2-[Cyclohexyl-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-(phenylmethyl)thiazolo[4,5-(phenylmethyl)thiazolo[
- 20 d]pyrimidin-7-yl]amino]-1-ethanol,
 - $\label{eq:continuous} $$(\pm)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,$
 - $(\pm)-N-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,$
- (\pm)-*N*-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,
 - N-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,
 - N-[2-[[7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-
- [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-acetamide,

- N^7 -(2-Methoxyethyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine,
- N^7 -(2-Ethoxyethyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine,
- 5 N^7 -(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]- N^2 -[2-(2-thienyl)ethyl]thiazolo[4,5-d]pyrimidine-2,7-diamine,
 - (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
- (±)-1-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 2-propanol,
 - (\pm) -2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-butanol,
 - $\label{lem:condition} $$(\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,$
- (2R)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
 - (\pm)-*N*,*N*-Diethyl-1-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinecarboxamide,
 - (2R)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol.
 - (\pm) -2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol,
 - (\pm) -2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino-acetamide,
 - 4-[1-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-3-azetidinyl]-1-piperazinesulfonamide,
 - 3-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,

25

- 2-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- (\pm) -2-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol,
- 5 (2R)-4-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol,
 - 2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-7(4H)-one,
- (\pm)-2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-10 7(4H)-one,

and their pharmaceutically acceptable salts and solvates.

- 7. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises:
- (a) when X represents -OH and R¹ is NH₂, heating a compound of general formula

wherein R² is as defined in formula (I); or

(b) when X represents -OH and R¹ is NH₂, reacting a compound of formula

- with a compound of general formula (IV), R² L¹, wherein L¹ represents a leaving group and R² is as defined in formula (I); or
 - (c) when X represents -OH or -NR¹³R¹⁴ and R¹ is a hydrogen atom, reacting a corresponding compound of formula (I) in which R¹ is NH₂, with a diazotizing agent; or
 - (d) when X represents -OH and R¹ is a group -NR³R⁴, reacting a compound of general formula

10

15

wherein L^2 represents a leaving group and R^2 is as defined in formula (I), with a compound of general formula (VI), R^3R^4NH , wherein R^3 and R^4 are as defined in formula (I); or (e) when X represents $-NR^{13}R^{14}$ and R^1 represents $-NR^3R^4$, reacting a compound of general formula

wherein L^3 represents a leaving group and R^2 , R^3 and R^4 are as defined in formula (I), with a compound of general formula (VIII), NHR¹³R¹⁴, wherein R¹³ and R¹⁴ are as defined in formula (I); or

(f) when X represents -NR¹³R¹⁴ and R¹ represents -NR³R⁴, reacting a compound of general formula

wherein L^4 is a leaving group, L^5 is a leaving group and R^2 is as defined in formula (I), initially with a compound of formula (VI) as defined in (d) above followed by reaction with a compound of formula (VIII) as defined in (e) above;

and optionally after (a), (b), (c), (d), (e) or (f) forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).

- 8. An intermediate compound of formula (V) as defined in claim 7.
 - 9. An intermediate compound of formula (VII) as defined in claim 7.

10

- 10. An intermediate compound of formula (IX) as defined in claim 7.
- 11. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 12. A process for the preparation of a pharmaceutical composition as claimed in claim 11 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 13. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 for use in therapy.
- 14. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 in the manufacture of a medicament for use in therapy.
- 15. A method of treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6.
- 16. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6.
- 17. A method according to claim 16, wherein the disease is psoriasis.

International application No.

PCT/SE 99/01333

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 513/04, A61K 31/519, A61K 31/426, A61P 17/06, A61P 29/00 // (C07D 513/04, 277:00, 239:00)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic d	ata base consulted during the international search (name	e of data base and, where practicable, searc	sh terms used)
C. DOCU	MENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where app	Relevant to claim No.	
A	J. Amer. Chem. Soc., Volume 73, Allison Maggiolo et al, "Stu PyrimidineSystems. VI. Some 5-d)-pyrimidines" page 4226	1-17	
A	J. Chem. Soc., 1970, J.A. Baker "Synthesis of Derivatives of pyrimidine. Part II"; pge 24 page 2484, left column, four	f Thiazolo(4,5-d) 178 - page 2484.	1-10
A	STN International, File CAPLUS, no. 1996:243961, Document no Gewald, K. et al: "New synth 4-aminoquinazolines and the J. Prakt. Chem./ChemZtg. (o. 125:10744, nesis of substituted ir hetero analogs":	1-10
X Furth	er documents are listed in the continuation of Box	See patent family annex	ζ.
"A" docume to be of "E" erlier do "L" docume cited to special : "O" docume means "P" docume	categories of cited documents: and defining the general state of the art which is not considered fracticular relevance occument but published on or after the international filing date and which may throw doubts on priority claim(s) or which is establish the publication date of another citation or other reason (as specified) and referring to an oral disclosure, use, exhibition or other and published prior to the international filing date but later than antity date claimed	"T" later document published after the int date and not in conflict with the applithe principle or theory underlying the "X" document of particular relevance: the considered novel or cannot be considered when the document is taken alone "Y" document of particular relevance: the considered to involve an inventive stere combined with one or more other such being obvious to a person skilled in the "&" document member of the same patent	cation but cited to understand invention claimed invention cannot be ered to involve an inventive e claimed invention cannot be p when the document is h documents, such combination eart
Date of the	e actual completion of the international search	Date of mailing of the international s	
8 Novem	mber 1999 mailing address of the ISA/ Patent Office	1 3 -12- 1999 Authorized officer	
Box 5055,	S-102 42 STOCKHOLM No. +46 8 666 02 86	Gerd Strandell/EÖ Telephone No. + 46 8 782 25 00	

International application No.
PCT/SE 99/01333

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No	
	, some appropriate, or allo relevant passages	TOTALL TO CIAINI 140	
A	STN International, File CAPLUS, CAPLUS accession no. 1990:235252, Document no. 112:235252, Ahluwalia, V.K. et al: "One-step synthesis of thiazolo(4,5-d)pyrimidines"; Indian J. Chem., Sect. B (1989), 28B(11), 964-5	1-10	
A	STN International, File CAPLUS, CAPLUS accession no. 1990:158124, Document no. 112:158124, Pawar, R.A. et al: "Studies on the Vilsmeier-Haack reaction. A versatile new synthesis of 4-chloro-2-phenylaminothiazole-5-carboxaldehyde and related fused heterocyclic compounds and heterocyclic Schiff's bases"; Indian J. Chem., Indian J. Chem., Sect. B (1989), 28B(10), 866-7	1-17	
A	US 2772164 A (CHARLES F.H. ALLEN ET AL), 27 November 1956 (27.11.56), column 1, line 49 - column 2, line 10; column 4, line 71 - column 5, line 6, the claims	1-10	
A	Chem. Pharm. Bull., Volume 6, 1958, Torizo Takahashi et al, "Studies on Pyrimidine Derivatives. I. Synthesis of Thiazolo (5, 4-d)pyrimidines and Related Compounds.(1).", page 334 - page 338, page 336(XI,XII); page 334	1-17	

International application No. PCT SE99/01333

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	rnational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: 15-17 because they relate to subject matter not required to be searched by this Authority, namely:
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
D 10	
Вох П	Observations where unity of invention is lacking (Continuation of item 2 of first sheet) rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

International application No. PCT/SE99/01333

Claims 15-17 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

Information on patent family members

International application No.

28/09/99 | PCT/SE 99/01333

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 2772164 A	27/11/56	BE DE	543978 A	00/00/00
		FR	1032668 В 1148762 А	00/00/00 00/00/00
		GB	789842 A	00/00/00

Form PCT/ISA/210 (patent family annex) (July 1992)